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2. Abstract 
Colorectal cancer is the fourth most common cancer in England, but English colorectal cancer 
outcomes have traditionally lagged behind those of similar income level countries. Reasons 
behind these poor outcomes are multi-factorial but include high numbers of elderly patients 
presenting with advanced disease and a stubbornly high rate of emergency admissions. 
Recent years have seen significant changes in the National Health Service’s approach to 
cancer treatment, alongside the development of population-level databases. 
 
This study uses population-level data, obtained through the National Cancer Data Repository 
to investigate how short-term outcomes of colorectal cancer patients within the English NHS 
between 1998 and 2010 have changed. Further, it seeks to evaluate the impact of the NHS 
Bowel Cancer Screening Program and novel technologies such as laparoscopic surgery and 
endoluminal stents on those outcomes.  
 
Risks factors for emergency colorectal cancer admission such as older age and increased co-
morbidity remain although short-term mortality rates (30 and 90-day) appear to be falling. 
Length of stay for colorectal cancer patients fell markedly over the study period, aided by the 
introduction of laparoscopic surgery, whilst those who engaged in the screening program were 
seen to have a greater likelihood of presenting electively and with early stage disease. 
Endoluminal stents have a clear, but as yet undefined role to play in the management of the 
colorectal cancer patient, but do appear to offer certain advantages to selected patients. 
 
Population-level data allows evaluation of interventions in healthcare and comparison of 
international outcomes. English colorectal cancer outcomes improved over the study period 
reported here, but are still not at the level of our European and international neighbours. There 
remains much work to do to improve these outcomes; it is likely that population-level data will 
play a pivotal role in this. 
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5. Introduction and Literature Review 
5.1. Colorectal Cancer: Incidence, Aetiology, Risk Factors and 
Staging 
Approximately 330,000 people are diagnosed with an invasive cancer within the United 
Kingdom (UK) each year and 50% of people alive in the UK today can expect to be diagnosed 
with cancer at some point during their life1. Since 2011, cancer has overtaken heart disease 
and stroke as the most common cause of death within the UK, accounting for 1 in 4 deaths 
(~160,000 deaths per year)1. The burden of disease cancer represents to the National Health 
Service (NHS) is huge. As the number of older people within the United Kingdom and England 
continues to increase, the on-going diagnosis and management of cancer is likely to be one of 
the major health issues that must be dealt with by future UK governments, allied healthcare 
workers and clinicians.  
 
Colorectal cancer (bowel cancer) is the fourth most common cancer in the UK and the third 
most common worldwide, behind breast and lung cancer2,3. There are approximately 40,000 
new cases of colorectal cancer (CRC) diagnosed in the UK each year, of which roughly half 
will be alive at five years following diagnosis3. Nevertheless in 2012 alone, CRC accounted for 
the deaths of 8795 men and 7392 women in the UK2. 
 
The incidence of colorectal cancer exhibits significant geographical variation but has been 
steadily rising throughout Europe and the UK since the 1970’s, with countries that ‘westernise’ 
rapidly seeing an attendant rise in rates of colorectal cancer4. 
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5.1.2. Figure 1: World Age-Standardised Incidence Rates per 100,000 
Population of Colorectal Cancer4 
 
Worldwide, the highest incidence of CRC is in Australia/ New Zealand and the lowest in 
Africa4. Within Europe, Slovakia has the highest incidence of CRC with 90.7 cases in men per 
100,000, whilst in comparison, Greece has the lowest incidence with 23.7 cases per 100,0004.  
 
Approximately two thirds of cases are cancers of the colon and one-third cancers of the 
rectum. There is a roughly equal incidence of colon cancer between men and women, but 
rectal cancer occurs more commonly in men, with 63% of cases of rectal cancer occurring in 
males4.  
 
The incidence of colorectal cancer is strongly related to age and weakly to socioeconomic 
deprivation5–7. In 2007-9, 72% of cases of CRC in the UK occurred in those aged over 65 and 
whilst CRC is 11% more common in the most socially deprived men compared with the most 
affluent, there is no significant difference for women4.   
 
In terms of prevalence, current estimates are that 3.26 million people (worldwide) were still 
alive up to five years after their diagnosis of colorectal cancer in 2008; UK prevalence rates 
are set out below4: 
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5.1.3. Figure 2: Bowel Cancer (C18-C20), One, Five and Ten Year Cancer 
Prevalence, UK, 31st December 20064 
 1 Year Prevalence 5 Year Prevalence 10 Year Prevalence 
Male 14,635 51,183 78,483 
Female 11,415 40,594 65,075 
Persons 26,050 91,777 143,558 
 
Whilst the exact aetiology of colorectal cancer remains unknown, in over 90% cases, the 
morphology of CRC is that of adenocarcinoma (including mucinous or colloid 
adenocarcinomas) arising from adenomatous polyps4. Signet-ring carcinomas, 
adenosquamous, medullary and other rare morphologies do occur, however, their incidence is 
minimal in comparison with adenocarcinoma.4 
 
CRC occurs most commonly on the left-hand side of the large bowel (splenic flexure, 
descending and sigmoid colon, rectum with approximately 60% of tumours being ‘left sided’4.  
5.1.4. Figure 3: Bowel Cancer (C18-21), Percentage Distribution of 
Cases within the Large Bowel, Great Britain, 2007-20094 
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Colorectal cancer is thought to arise from a series of genetic ‘hits’ within specific oncogenes 
and tumour suppressor genes, resulting in the development of the adenoma-carcinoma 
sequence. At least 4 successive ‘hits’ are required to ensure progression to carcinoma, with 
the tumour suppressor genes APC, SMAD4 and TP53 and the oncogene KRAS being the 
prime targets for these ‘hits’8. Eighty-five per cent of cases of colorectal cancers are classified 
as ‘sporadic’ however, and direct initiating factors for these ‘hits’ remain  unknown8. 
 
Of the remaining 15% of cases, some clearly defined risk factors are apparent. Genetic factors 
in the forms of familial colorectal cancer (those who have a first degree relative affected <45 
years of age, or two first degree relatives affected), Familial Adenomatous Polyposis (FAP), 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC or Lynch Syndrome), Peutz-Jeghers 
syndrome and juvenile polyposis are well documented9. Inflammatory bowel disease 
(Ulcerative Colitis and to a lesser extent Crohn’s disease) and the Acquired Immune 
Deficiency Syndrome (AIDS) are well recognised as risk factors for colorectal cancer9. Other 
risk factors identified but without a clear causal relationship include age, previous polyps/ 
colorectal cancer, race, type 2 diabetes, diet, lifestyle, obesity, smoking and excess alcohol 
consumption10–12. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) have been noted, through 
their inhibitory effect on cyclo-oxygenase-2 (and subsequent toxic effect on gastro-epithelial 
cells), to have a chemopreventive effect on adenoma formation as far back as 198113. Until 
recently, the dosages required to achieve chemopreventive effects have been outweighed by 
the well documented adverse cardiovascular side effects13. A recent study by Nan et al. 
however, has suggested that a patient’s individual genotype may confer either an increased 
risk, no risk or protective risk of CRC with NSAID use. It is perhaps therefore feasible in the 
future that targeted use of NSAIDs may well benefit some patients in reducing their CRC 
risk14.  
 
Adenoma formation in the hereditary colorectal cancer syndromes (FAP, HNPCC, Peutz-
Jeghers syndrome, juvenile polyposis) is defined by germ-line mutations predisposing to polyp 
formation9,11,15. APC, the tumour suppressor gene involved in FAP appears to be a multi-
functional gene, regulating several intracellular processes. The key ‘hit’ however, seems to be 
the loss of the ability to regulate intra-cellular β-catenin levels15. This loss results in a number 
of downstream effects, disrupting cell adhesion, migration and signal transduction, amongst 
others but ultimately allowing progression to malignant transformation15. HNPCC is 
characterised by mutations in mismatch repair genes responsible for repairing mistakes made 
during DNA replication. Loss of this repair mechanism allows rapid destabilisation of the 
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genome and therefore development of malignancy16. Rate of transformation of polyps is 
significantly faster in HNPCC than in FAP, as would be expected by its underlying 
pathophysiological mechanism.  
 
Crohn’s Disease and Ulcerative Colitis are underpinned by inflammation and proliferation of 
the colonic epithelium during episodes of active disease that predispose the individual to 
colorectal cancer. Although colorectal cancer secondary to inflammatory bowel disease 
accounts for only 1-2% of all colorectal cancers, the incidence and prevalence of colorectal 
cancer in the inflammatory bowel disease patient population is still significantly higher than in 
the general population17. As such, the mean age of developing colorectal cancer is lower than 
in sporadic cases, with the magnitude of risk related to age at diagnosis and extent of disease, 
with pancolitis carrying the greatest risk. Thus, the risk of developing colorectal cancer in a 
patient with inflammatory bowel disease is approximately 0.5-1% per year, 8-10 years after 
diagnosis17.  
 
African Americans and Ashkenazi Jews have been found to be at higher risk of developing 
colorectal cancer than other populations11. The movement of the Ashkenazi Jews across 
Europe, where they settled and married within tight communities, may have allowed founder-
mutation effects to occur thus explaining the increased incidence in this group11. African 
Americans suffer from an increased risk of colorectal cancer for as yet unclear reasons but are 
thought to be related to past exposure to underlying risk factors, access to diagnostics, timely 
intervention and exposure to the Western lifestyle 11,18. 
 
Diet has long been recognised as a modifiable risk factor for cancer within industrialised 
nations12. Type 2 diabetes has been found to be independently associated with the 
development of colorectal cancer, even after adjustment for conditions associated with the 
development of both colorectal cancer and type 2 diabetes such as obesity19. Diet has been 
considered to be a possible risk factor for colorectal cancer since the 1960’s when Burkitt 
proposed the hypothesis that low fibre diets and subsequent slow colonic transit may be 
implicated in the development of colorectal malignancy8. Data from the on-going EPIC trial 
(European Prospective Investigation into Cancer and Nutrition) study has now been released, 
which provides strong evidence for the role of fibre in prevention of colorectal cancer, 
suggesting that in populations with a low dietary fibre intake, doubling intake could result in a 
40% reduction in rates of colorectal cancer. Processed or red meat consumed in large 
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quantities (160g or two portions/ day) was associated with a 35% increase in colorectal 
cancer, whilst consumption of fish was found to be protective20.  Energy intake, body mass 
index and degree of physical activity have been shown to be related to colorectal cancer risk 
(with lower levels of intake and higher levels of activity giving a lower risk), although the 
underlying mechanisms remain unclear21.  
 
Colorectal cancer is divided into stages using either the Tumour, Nodes, Metastasis system 
(from the American Joint Committee on Cancer) or the system devised by the British 
pathologist Cuthbert Dukes, the Dukes criteria (note Dukes ‘D’, representing metastatic 
disease was added later to the original classification)22,23. The classification system proposed 
by Astler and Coller in 1954 and now modified to the Modified Astler Coller (MAC) system, is 
much less frequently used24. Each system is based around depth of penetration of the tumour 
into the layers of the bowel, invasion into surrounding structures (including lymph nodes and 
blood vessels) and spread to distant sites. 
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5.1.5. Figure 4: Staging of Colorectal Cancer* 
Stage TNM Dukes’ MAC Depiction 
0 Tis, N0, 
M0 
– – 
 
I T1, N0, 
M0 
A A 
 
 
 
T2, N0, 
M0 
A B1 
IIA T3, N0, 
M0 
B B2 
 
IIB T4a, N0, 
M0 
B B2 
IIC T4b, N0, 
M0 
B B3 
IIIA T1–T2, 
N1/N1c, M0 
C C1 
 
 
T1, N2a, M0 C C1 
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*Adapted from the National Cancer Institute website 
(http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/Page3#Section_331)25 
 
Stage TNM Dukes’ MAC Depiction 
IIIB T3–T4a, 
N1/N1c, M0 
C C2 
 
 
T2–T3, N2a, 
M0 
C C1/C2 
 
T1–T2, N2b, 
M0 
C C1 
IIIC T4a, N2a, 
M0 
C C2 
 
 T3–T4a, 
N2b, M0 
C C2 
 
T4b, N1–N2, 
M0 
C C3 
IVA Any T, Any 
N, M1a 
D - 
 
IVB Any T, Any 
N, M1b 
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5.2. Management of Colorectal Cancer  
Patients with colorectal cancer usually present first to their primary care physician, and most 
often with a change in bowel habit, change in appetite/ unintentional weight loss, blood in their 
stools or unexplained anaemia26. Within the UK, approximately 20% of patients with colorectal 
cancer will present as an emergency, usually with either obstruction or perforation of their 
bowel27. 
 
Throughout the United Kingdom, the National Institute for Health and Care Excellence (NICE), 
the Scottish Intercollegiate Guidelines Network (SIGN) and the Association of Coloproctology 
of Great Britain and Ireland (ACPGBI) have each produced guidelines for the diagnosis and 
management of colorectal cancer3,28,29. Each group recommends colonoscopy and biopsy for 
the diagnosis of CRC, although each accepts that CT colonography may be used as an 
alternative in the elderly or in difficult to reach right sided tumours. Each patient should receive 
a pre-operative CT scan of their chest and abdomen to assess the degree of tumour invasion 
and for the presence of metastases. Positron Emission Tomography (PET) scanning may also 
be used to assess for the presence of metastases not visible on conventional imaging 
although this is not standard practice, except when dealing with potentially curative re-
resections.  Emergency patients with perforated tumours who are peritonitic are excluded from 
this requirement, where emergency surgical intervention is lifesaving. Those with rectal cancer 
should expect to receive pre-operative MRI scanning of their pelvis in order to stage the 
tumour, assess whether a clear resection margin is possible and the risk of recurrence. 
Endoanal ultrasonography is recommended by NICE for the assessment of those undergoing 
local/ transanal excision of early stage disease3. 
  
5.2.1. Surgery for Colorectal Cancer 
Complete surgical excision of the tumour (R0 resection) forms the mainstay of treatment for 
CRC and is usually considered a basic requirement for successful treatment. Whilst early 
stage disease may be treated endoscopically, the majority of patients require surgical excision 
of the affected segment of bowel.  
 
The bowel and its mesentery are excised segmentally depending on the location of the 
tumour, with the ‘radicality’ of surgical excision being dependent on the blood supply to the 
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affected segment, the extent of any lymphatic invasion and/or spread to distant structures (see 
Figures 5 and 6).  
5.2.1.1. Figure 5: Colectomies for Colon Cancer* 
 
The practice of rectal surgery has changed markedly over the last 3 decades. In the mid-
1980’s the requirement for 5cm distal excision of rectal cancers began to be challenged, with 
the realisation that distal mural spread of the tumour is seldom greater than 2cm30. Thus 
necessity for patients to lose their anal sphincters (through abdominoperineal excision) to 
achieve adequate oncological clearance, alongside advancements in stapling technology 
which allow safe distal rectal or colo-anal anastomoses to be performed, resulted in anterior 
resection becoming the standard procedure for rectal cancer31,32.  
 
The 1990’s saw the abandonment of conventional blunt dissection of the rectum with the 
introduction of Total Mesorectal Excision (TME). Heald et al. and Enker et al. demonstrated 
that through complete removal of lymphovascular tissue and a free circumferential margin 
surrounding the tumour (through sharp perimesorectal dissection) substantially lower rates of 
disease recurrence could be achieved33–35. 
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5.2.1.2. Figure 6: Rectal Resections for Rectal Cancer* 
 
*Figures 5 & 6 taken from South Australia Cancer Council Website36 
(http://www.cancersa.org.au/information/a-z-index/surgery-for-bowel-
cancer#Surgery%20for%20rectal%20and%20anal%20cancers) 
 
5.2.2.  Adjuvant Therapies 
Despite the best efforts of surgery with curative intent, the risk of disease recurrence in 
colorectal cancer following surgical excision remains high (up to 50% at 2 years in those with 
high grade rectal cancer37). Neoadjuvant therapies (chemo or radiotherapy), in the pre-
operative period, aim to downstage the disease, increasing the likelihood of achieving clear 
resection margins, limiting the chance of recurrence. For those with high-grade disease (and 
therefore high chance of micro-metastatic spread), post-operative chemotherapy may be 
given. 
 
Adjuvant therapy in colon cancer centres is based around the administration of chemotherapy, 
as use of radiotherapy would cause unacceptable morbidity due to damage to other 
structures. No single, unifying guideline exists for use of chemotherapy in colon cancer but 
current NICE guidelines suggest use of capecitabine as monotherapy or oxaliplatin in 
combination with 5-fluorouracil and folinic acid for those with high-risk stage II or stage III 
colon cancer. Cetuximab along with folinic acid, fluorouracil and oxaliplatin is recommended 
as first line therapy in those with advanced (stage IV) disease3. Recommendations regarding 
second line agents vary, but in general are based around the use of capecitabine along with 
irinotecan3.  
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Radiotherapy in rectal cancer may be used either to help achieve locoregional control (short 
course preoperative radiotherapy, SCRT) or may be used in tandem with chemotherapy (long 
course chemo radiotherapy, LCRT) where the TME envelope is threatened or the patient has 
advanced stage disease38 It is recommended that use of radiotherapy in rectal cancer should 
be decided following multi-disciplinary team discussion and by the risk of disease recurrence 
as determined by magnetic resonance imaging (MRI) scanning of the pelvis39.  
 
5.2.2.1. Figure 7: Risk of Local Recurrence as Predicted by MRI 
Risk  of local recurrence for rectal cancer as predicted by MRI3 
Low 
• cT1 or cT2 or cT3a and 
• no lymph node involvement 
 
Moderate 
• any CT3b or greater, in which the potential 
surgical margin is not threatened 
• any suspicious lymph node not threatening 
the surgical margin 
• the presence of extramural vascular 
invasion 
 
High 
• a threatened (< 1mm) or breached 
resection margin or 
• low tumours encroaching onto the inter-
sphincteric plane or with levator involvement 
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Short course preoperative radiotherapy is usually given as 25Gy in 5 daily fractions over 1 
week, with surgery the following week. Long course chemo-radiotherapy (LCRT) is usually 
given as 45-50GY in 25 daily fractions over 5 weeks alongside 5-FU based chemotherapy, 
followed by surgery 4-8 weeks after completion of radiotherapy (Figure 8). 
 
5.2.2.2. Figure 8: NICE Guidelines for use of Preoperative   
Radiotherapy in Rectal Cancer 
Recommendation for Preoperative Radiotherapy3 
Risk of Recurrence  
Low 
Do not offer short-course preoperative 
radiotherapy (SCRT) or chemo-radiotherapy 
to patients with low-risk operable rectal cancer, 
unless as part of a clinical trial 
 
Moderate 
Consider SCRT then immediate surgery for 
patients with moderate-risk operable rectal 
cancer. Consider preoperative chemo-
radiotherapy with an interval to allow tumour 
response and shrinkage before surgery for  
patients with tumours that are borderline 
between moderate and high risk 
 
High 
Offer preoperative chemo-radiotherapy with an 
interval before surgery to allow tumour 
response and shrinkage (rather than SCRT), to 
patients with high-risk operable rectal cancer. 
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5.2.3.  Current English Colorectal Cancer Survival 
For those diagnosed with cancer in the UK today, prospects of survival have changed beyond 
all recognition over the last 40 years; 50% would have been alive at 1 year in the 1970’s , 
compared with 50% at 10 years in 20111. Survival from colorectal cancer is no different, in 
1971-2, a man diagnosed with CRC would have had a 47% chance of surviving one year 
(45% for women), compared with 77% in 2010-11 (73.9% for women).40.  
Survival  for those diagnosed with colorectal cancer is currently highest in the age group 60-
69, with lower survival figures seen in younger patients and a progressive decline in survival 
occurring from age 70 onwards41. Not surprisingly, survival varies by stage of disease at 
diagnosis. Almost all those with Stage I disease survive at least a year (98% of men, 100% of 
women) as compared to 40% of men with Stage IV disease and 33% of women. By 5 years 
from diagnosis, 95% of those with Stage I disease will still be alive, but only 7% of those with 
Stage IV disease41. 
 
5.2.4.  Purpose of the Study 
Whilst there is clear evidence that colorectal cancer outcomes in England (and Wales) have 
improved over time,  outcomes trail behind those of equivalent income level European 
countries42. A major contributing factor is the stubbornly high rate of emergency presentation 
amongst English patients, with high levels of elderly patients presenting as emergencies with 
advanced disease43. Population level data provides researchers with a unique opportunity to 
observe chronological sequences, links between clinical and geographic details and to assess 
the impact of changing clinical management practices on national level outcomes.  
 
Thus, this study attempts to understand why English colorectal cancer outcomes continue to 
be persistently poor in comparison to Europe. It aims to assess and to highlight the differing 
short-term outcomes of elective and emergency CRC patients between 1998 and 2010 treated 
within the English NHS and to suggest ways in which these cheerless comparisons may be 
improved.  
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5.3. Literature Review 
5.3.1. Identification of Literature 
Literature for this review was identified through use of Ovid Medline (1996 to Week 1 January 
2018) and Embase (1996 to Week 1 March 2018) using Medical Subject Headings (MeSH), 
and supplemented through Google Scholar (‘exact phrase’) and review of the references of 
relevant publications.  
 
5.3.2.  Variation in Cancer Incidence and Outcomes 
In 2012, there were an estimated 14.1million new cases of cancer diagnosed worldwide.  53% 
of these cases occurred in men and 47% in women, with lung cancer being the most common, 
followed by female breast, bowel and prostate cancer 44.  Over the last 40 years, the global 
incidence of cancer has remained relatively static, although stomach cancer has declined 
(most likely as a result of the discovery of H.Pylori as a risk factor) and lung cancer 
(secondary to tobacco smoking) increased as relative proportions of the total44.  If population 
growth continues at its projected rate, alongside the projected incidence of major cancers, it is 
estimated that there will be 23.6million new cases of cancer diagnosed worldwide by 203044.  
 
The global cancer incidence varies significantly depending upon a country’s economic 
development (2012 estimates, Australia/ New Zealand: 318 per 100,000, Western Africa: 19 
per 100,000), with economically developing countries having markedly higher rates of cancer 
due to infectious causes (e.g. liver, stomach, cervix) and economically developed countries 
being disproportionately affected by cancers associated with the Western lifestyle (lung and 
bowel)44,45. Overall however, incidence rates tend to be higher in developed countries (as 
cancer, as a general rule, is a disease of old age, with high numbers of younger people dying 
in less developed countries of non-cancer related causes).44 
 
Global cancer mortality exhibits significant variation with an estimated 8.2 million cancer 
deaths occurring in 201244. Recent years have seen striking improvements in cancer mortality, 
especially within developing or economically transitioning countries, but wide disparities still 
remain46. More developed regions of the world report age standardised rates of mortality for all 
cancers in men of 108.5 per 100,000. In comparison, less developed regions report mortality 
rates of 98.4 per 100,00047. What remains striking however, is that within industrialised 
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nations, whilst rates of cancer mortality have improved at a similar rate, disparities in 
outcomes have remained static, despite the improvement in overall mortality47.  
 
5.3.3. Worldwide Variation in Colorectal Cancer Outcomes 
Colorectal cancer is estimated to make up approximately 9.7% of the world’s yearly cancer 
burden, with marked geographic differences in both incidence and survival44. The highest 
recorded incidence is in Australia and the lowest in Western Africa (although accurate figures 
for this region are hard to verify)47 Worldwide, colorectal cancer is the cause of 694,000 
deaths each year, with mortality being highest in Central and Eastern Europe (20.3 deaths per 
100,000 men, 11.7 deaths per 100,000 women respectively) and lowest in Western Africa (3.5 
per 100,000 for men,3.0 per 100,000 for women). Within developed regions of the world, 
incidence and mortality rates from colorectal cancer have largely been falling over recent 
years (thanks mainly to better awareness and earlier treatment), whilst rates of both incidence 
and mortality in countries with more limited health infrastructures continues to increase47. 
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5.3.3.1. Figure 9: Estimated Worldwide Incidence and 
Mortality from Colorectal Cancer 201247  
 
 
Accurate statistics for the incidence of and survival from all forms of cancer, not just colorectal 
are a fundamental requirement to understanding why, and how variation in cancer survival 
occurs. Prior to the 1960’s, international comparison of cancer related outcomes was 
impossible, as few cancer registries had been in existence long enough to provide reliable 
data48. In 1964, an attempt was made to compare the cancer survival rates of northern 
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European countries with those of the state of Connecticut. Survival was shown to be, in most 
cases, significantly better for American than European patients and whilst development of 
national cancer registries continued, no further efforts to compare international survival rates 
or to understand international variations in survival were made until the publication of the 
EUROCARE project in 199549,50.  
 
The EUROCARE project (s) are co-operative,  cancer registry based studies which aim to 
compare cancer prevalence, care, survival and time trends across various European 
countries. Each project compares the outcomes of patients diagnosed within a set time period 
and illustrates how European outcomes vary and how trends in cancer epidemiology are 
developing. EUROCARE data was first used to evaluate colorectal cancer outcomes by Sant 
et al. to compare survival for colon cancer patients between 1978-85 in 10 European 
countries. Mean European 5 year cumulative survival was found to be 40%, but significant 
inter-country variability was seen with Switzerland, Finland and the Netherlands achieving 
results that were significantly above the European mean. Most of the remaining countries 
(France, Germany, Italy, Denmark and most areas of England) achieved survival figures 
whose confidence intervals sat astride the European mean, however, Cracow in Poland (22%) 
and one area of England (Mersey) (29%), achieved figures that were significantly below the 
mean. This inter-country variability was felt by Sant et al. to be most likely due to differences in 
healthcare provision, quality of care and stage of disease at presentation.51  
 
The expanded EUROCARE-2 project included 3 473 659 patients from all cancer sites, 
diagnosed between 1978 and 1989 in 17 countries, from 45 different registries52. In relation to 
colorectal cancer, Switzerland, Austria and the Netherlands were all noted to have high levels 
of 5-year relative survival (>45%), whilst survival in Slovenia and Poland was low (38%) and 
intermediate in the UK (41%)53.  Rates of surgical resection were seen to vary widely from 
>85% in Switzerland, the Netherlands and France to less than 60% in Estonia and Poland, 
with most of the differences in survival being seen in the first 6 months after diagnosis. 
Survival at 5-years was seen to be much more homogeneous53.  
 
EUROCARE-2 raised numerous questions as to what may underlie the differences in survival. 
Was it rates of surgical resection that improved survival or was it in fact that patients were 
being diagnosed earlier in differing European countries (and therefore appearing to survive for 
a longer period)? An attempt to address these questions (and to build upon the data 
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presented in EUROCARE-2) was undertaken  through a high resolution study of colorectal 
cancer outcomes by Gatta et al. Gatta et al. reviewed the outcomes of 2720 patients 
diagnosed in 11 European cancer registries between 1988 and 1991 (although it remains 
unclear from the paper exactly how these patients were selected)54. Information on stage at 
diagnosis (TNM) and other determinants of stage (results of CT or ultrasound scanning of the 
liver, number of lymph nodes harvested at resection) alongside information on the surgical 
resection performed was used to compare outcomes at 3 years following diagnosis. Rates of 
surgical resection varied enormously, from 93% in Côte d’Or to 53% in Cracow, as did rates of 
elective surgery (87% Côte d’Or, 56% Cracow).  Similar variability was seen in 3-year relative 
survival, with survival ranging from 59% in Modena to 25% in Cracow. The UK registry with 
the worst survival reported a 5-year relative survival figure of 38% (Thames)54. The relative 
risk of death at 3 years showed much less variability once stage at diagnosis was taken into 
account, although the Cracow and Thames regions still performed poorly, even after these 
adjustments. Gatta et al. concluded therefore that there was wide variation in diagnostic and 
surgical practice throughout Europe but that the variations in outcome were, in actual fact, 
largely due to stage at diagnosis54.  
 
More recent updates of the EUROCARE project (EUROCARE 3-5), have again demonstrated 
clear evidence of variation in European cancer outcomes and that whilst cancer outcomes 
were, in general improving throughout Europe, the inter-country differences in survival  was 
failing to close55,56. The authors of the EUROCARE-4 study also noted that the UK and 
Denmark, whilst having similar levels of total national expenditure on health to other high 
income level countries, achieved a lower all cancer survival rate, suggesting that the UK and 
Denmark may not have been allocating healthcare resources efficiently56.  
 
The most recent EUROCARE study, EUROCARE-5, now reports the results of over 10 million 
patents, diagnosed from 1995 to 2007 and followed up to 2008. 5-year relative survival, again, 
improved for almost all cancers over the study period, with marked improvements in survival 
from prostate cancer, non-Hodgkin lymphoma and rectal cancer57. For colorectal cancer, 
diagnosed between 2000-2007, the 5-year age standardised European mean mortality for 
colon cancer was 57.0% and 55.8% for rectal cancer, with high performing countries such as 
Iceland achieving 62.0% for colon and 73.2% for rectal cancer. In comparison, UK survival 
figures were 51.8% (colon cancer) and 53.7% (rectal cancer)57. Only former Eastern Bloc 
countries such as Bulgaria, Latvia and Lithuania achieved poorer outcomes57.  
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Throughout the series of EUROCARE publications, the authors have consistently argued that 
it is stage at diagnosis that underlies the disparity in European colorectal cancer outcomes. 
Whilst they acknowledge the role of cancer biology, wide variations in diagnostic and surgical 
practices and the impact of socioeconomic and lifestyle factors, it is stage at diagnosis that is 
given as the primary reason for the differences57. How differences in disease characteristics 
(i.e. stage at diagnosis) affects survival in French and English CRC patients was explored by 
Dejardin et al., who compared the outcomes of 3 population based cancer registries in France 
to one in England. French patients were more likely to receive a resection with curative intent 
within six months of diagnosis at all stages of disease, with the difference in likelihood of 
resection increasing in line with the stage of disease58. A larger proportion of English patients 
were also noted to have died within a year of diagnosis (compared with the French patients) 
and that if an English patient survived for at least a year, their long term survival was similar to 
that of their French counterpart58. Thus, Dejardin et al. implied that it may not only be stage at 
diagnosis that underlies differences in survival, particularly for English patients, it may well 
also be initial management and likelihood of receiving a resection with curative intent58.  
 
How colorectal cancer outcomes between English and other European patients differ was 
explored by Engholm et al. and Morris et al. Engholm et al. analysed 5-year relative survival 
data from patients diagnosed between 1994 and 2000 from 11 UK registries and 4 from 
Nordic countries (Denmark, Finland, Norway and Sweden). A 30% higher risk of death was 
found amongst UK and Danish patients in the first 6 months after diagnosis, compared with 
Finnish, Norwegian or Swedish patients59.  The excess deaths were attributed to differences in 
early patient management, diagnostic processes and co-morbidity amongst UK and Danish 
patients59. Morris et al. compared outcomes of patients diagnosed and managed with CRC in 
England, Norway and Sweden between 1996 and 2004, measuring 5-year relative survival 
and excess deaths stratified by age and period of follow-up. 5-year relative survival of English 
patients (51.1%) was significantly lower than that of either Norwegian (57.9%) or Swedish 
patients (59.9%), with the greatest excess of deaths occurring in older patients within the first 
3 months of diagnosis60. Morris et al. therefore concluded that England seemed to have a 
higher percentage of older patients presenting with more rapidly fatal (i.e. more advanced 
stage and more aggressive) disease than her Nordic counterparts60. 
The generally poorer outcomes of English patients, compared with their European neighbours, 
would therefore seem to be due to a mix of stage at diagnosis, initial management/ likelihood 
of receiving a major resection and England having a high percentage of patents who present 
late with aggressive disease57–60. How age, stage of diagnosis, co-morbidity and initial 
management affects  excess deaths in Danish patients was the subject of a study by Iversen 
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et al61. Iversen et al. compared the outcomes of patients aged over 75 with younger patients 
who were diagnosed and treated for colorectal cancer between 1977- 1999 in Denmark. Short 
and long term survival improved for both groups, whilst improvements in survival were 
greatest amongst the elderly, due to increasing use of radical resection within this group61. By 
the time of the most recent period analysis (1997-1999), there were only minor differences in 
the relative survival of both younger, middle aged and older patients61. There are marked 
similarities between the English and Danish healthcare systems and the demographics of their 
populations. Whilst there is good evidence that England has high numbers of patients 
presenting with advanced disease, Iversen et al. provide evidence that the initial management 
of colorectal cancer patients may also have a significant impact upon their survival60,61.  
 
Which factors may be associated with an early death (< 1 year following diagnosis) in English 
colorectal cancer patients was explored by Downing et al. through the use of a retrospective 
cohort study. Downing examined all patients diagnosed and treated for CRC between 2006 
and 2008 within the English NHS; of which 11.5% of colon cancer patients died within 1 month 
of diagnosis and 5.4% of rectal cancer patients. The proportion of patients who died before 1 
month significantly decreased over the study period, potentially implying that recent changes 
made to the management of CRC patients within the English NHS are having an effect on 
likelihood of  (at least initial) survival. Those most likely to die early within Downing’s study 
however, were the elderly, those from deprived socioeconomic backgrounds, those with 
advanced disease at presentation, those with multiple co-morbidities and those who received 
no form of radical treatment (i.e. surgery or palliative chemotherapy)62. 
  
A further study by Morris et al., examined the 30-day post-operative mortality in all those who 
underwent major resection for colorectal cancer diagnosed between 1998 and 2006 in the 
English NHS; the findings of which mirrored those of Downing et al. This study again found 
that those most likely to die early after surgery were the elderly, those with multiple co-
morbidities, advanced stage of disease, a deprived socioeconomic background but also added 
the degree of operative urgency (those with greater urgency doing less well)63. Significant 
variation in rates of post-operative mortality dependent upon region was also seen, suggesting 
that there is much variation in surgical practice throughout England and hence the potential 
outcomes that are achieveable63.  
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The impact of initial post-operative management on outcomes  was highlighted by a Dutch 
study, which assessed the contribution of hospital volume and patient characteristics to 30-
day postoperative mortality (Osler et al.)64. 11, 287 patients (both elective and emergency) 
from 43 surgical departments between 2001 and 2004 were included within the study. Rates 
of 30-day postoperative mortality varied from 3.1% to 44.1% after emergency colon cancer 
surgery, with emergency patients 5 times more likely to die (odds ratio 4.6) in the worst 
performing hospitals compared with the best64. For those who had elective colon or rectal 
cancer surgery, differences in mortality were small and insignificant between all hospitals. 
  
Emergency admission and/or operation, clearly therefore, have a significant negative impact 
on survival in colorectal cancer. How rates of emergency presentation differ throughout 
Europe are difficult to accurately verify but have recently been reported to vary from 12% in 
Greece  up to 25% in Norway65. English rates have been quoted as being ‘stubbornly high’ at 
~20%43. English colorectal cancer patients therefore would appear to have a high rate of 
emergency presentation, often with advanced disease, with more co-morbidity and at an older 
age in comparison to other, similar income level countries. This does not adequately explain 
England’s poor survival record for CRC patients however; England and Norway have similar 
levels of emergency presentation but wide differences in outcome. English patients often 
appear to present late, in an unplanned manner and are subject to significant variation in their 
initial management. Understanding why English patients present in this fashion, and what may 
be done to improve early diagnosis and early post-operative management, has the potential to 
significantly improve English CRC outcomes. 
 
Differences in colorectal cancer outcomes do not just exist between English and European 
patients of course; there is also marked variability in outcome in colorectal cancer outcomes 
between England and other first world nations, such as America and Australia. Whilst the 
EUROCARE studies were pivotal in highlighting differences in European cancer outcomes, 
Gatta et al. made use of data from EUROCARE-2 and the American Surveillance, 
Epidemiology and End Result (SEER) programs to compare the outcomes of 738,076 
European patients and 282, 398 American patients diagnosed with one of 12 cancers between 
1985 and1989. Outcomes for European patients were significantly worse for most cancers 
compared with for those of American patients and colorectal cancer was no different. 5-year 
relative survival rates for colon cancer were 60% in American patients versus 47% in 
European patients and for rectal cancer, 5-year survival was 57% in American patients and 
43% in European patients. The authors suggested that the most likely reason underlying this 
35 
 
 
difference was the increased chance of American patients being diagnosed early, at a less 
advanced stage and therefore with a greater chance of long-term survival48. 
 
An attempt to assess differences worldwide cancer outcomes was undertaken by Coleman et 
al. in the CONCORD study. CONCORD began as an extension of the EUROCARE-3 project 
but also developed the work of Gatta et al. to assess the cancer related outcomes of 1.9 
million patients (aged 15–99 years), diagnosed during 1990-94 and followed up until 1999, 
with either breast (women), colorectal or prostate cancer, from 101 cancer registries, across 
31 countries and 5 continents.66 Again, wide differences in international cancer survival were 
seen, and although those differences were present for almost all European countries, in 
relation to colorectal cancer, United Kingdom patients fared particularly badly. American 
patients achieved age-standardised, 5-year relative survival figures from CRC of 58.6% for 
men and 60.0% for women. In comparison, the European average was 45.3% in men and 
48.1% in women. High achieving European countries such as Sweden managed 52.8% for 
men and 56.2% for women, but the UK only achieved 42.3% for men and 44.7% for women. 
Only former Eastern bloc countries such as the Czech Republic fared worse (33.8% (men) 
and 38.3% (women))66.  
 
The survival of colorectal cancer patients in the CONCORD study, was looked at in detail by 
Allemani et al, who noted rates of Dukes’ A and B tumours were similar between the United 
States (US) and Europe, whilst Dukes’ C was more frequent in the US and Dukes’ D more 
frequent in Europe67. Resection with curative intent was found to be significantly more likely in 
the US (85% patients) compared with Europe (75% patients). Use of adjuvant chemo and/ or 
radiotherapy was also much higher in the US than in Europe, with 28% of Dukes’ B colon 
cancer patients receiving chemotherapy in the US compared with 20% in Europe. For Dukes’ 
C patients, 56% received chemotherapy in the US, in contrast to 47% in Europe. Those with 
rectal cancer demonstrated a similar disparity with 47% of Dukes’ A-C patients receiving 
radiotherapy in the US compared with 37% of European patients. As a consequence, survival 
in American CRC patients was noted to be between 12-14% higher than in comparable 
European patients with this difference in survival being attributed to earlier stage at diagnosis, 
more extensive use of surgery and neoadjuvant therapies in American patients.67 
  
Differences in colorectal cancer outcomes do not occur only between American and English 
patients however. Yu et al. examined the survival of all patients diagnosed with either breast 
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(female), lung or colorectal cancer diagnosed between 1992 and 2000 and registered with 
either the Northern and Yorkshire Cancer Registry and Information Service (NYCRIS) or the 
New South Wales Central Cancer Registry (NSWCCR). For all cancers studied, English (i.e. 
NYCRIS)  patients reported a 47-58% higher risk of excess death compared with those of 
New South Wales (i.e. NSWCCR), whilst 5-year age-standardised relative survival rates for 
CRC cancer patients were 50.3% in English patients and 60.1% in Australian patients 
respectively68.  
 
Yu et al.’s work is especially important in establishing that a real difference exists in cancer 
related outcomes, and colorectal cancer in particular, between England and other first world 
nations. One of the frequent criticisms levied at international comparisons of outcome data are 
the differences in cancer registration methods used and the completeness of available data.  
Such differences present numerous potentially confounding (and therefore explanatory) 
variables, but the strength of Yu et al.’s work is that English and Australian cancer registration 
and mortality systems are directly comparable.  Both registries (i.e. NYCRIS/ NSWCCR) are 
well established, containing high quality data, with high levels of completeness and rates of 
survival that are similar to those reported at a national level6869,70. Thus Yu et al.’s work 
provides compelling evidence that the differences in outcomes are real and that UK cancer 
outcomes are genuinely inferior to those of Australia. 
 
The results of the International Cancer Benchmarking Project (ICBP) provide further evidence 
that UK cancer outcomes are inferior to those of Australia and other first world nations. The 
ICBP was setup to look specifically at international disparities in cancer survival. It assessed 
the survival of 2.4million adults diagnosed with primary lung, colorectal, breast (women) or 
ovarian cancer in 12 jurisdictions in 6 countries (Australia, Canada, Denmark, Norway, 
Sweden and the UK) between 1995-2007, with follow-up to 31st December 200766. Survival 
improved for all cancers over the study period but was persistently higher for those treated in 
Australia, Canada and Sweden, intermediate in Norway and lower for those in Denmark and 
the UK (in this study, UK refers to England, Wales and Northern Ireland)66.  
 
In relation to colorectal cancer, 732,005 patients were treated over the course of the ICBP.  In 
that time survival increased at a similar pace within each country, but wide deficits in were 
seen between the UK and Denmark when compared to Australia, Canada and Sweden. For 
the most recent period (2005-2007), age standardised, 1 year relative survival in the best 
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performing nation (Australia) was 84.7%. The UK in comparison achieved 74.7% and 
Denmark 77.7%. By 5 years, the differences in relative survival were 66.4% (Australia) and 
55.8% (Denmark) and 53.6% (UK)66. Data quality, classification and other confounding 
variables were not felt to be likely explanations for the differences seen in survival, as the 
patterns in cancer related outcomes were consistent with later diagnosis and differences in 
management of patients, especially for those patients managed in the UK or Denmark66.  
 
Stage at diagnosis has been suggested by several authors as a key explanation behind the 
differences in international colorectal cancer survival54,67. The impact stage at diagnosis has 
on the outcome of colorectal cancer patients was investigated in detail by Maringe et al., who 
analysed 313,852 patients from Australia, Canada, Denmark, Norway, Sweden and the UK, 
treated for colorectal cancer between 2000 and 2007. Again, 1 and 3 year survival was 
persistently worse in the UK and Denmark, with the UK achieving a 1 year survival rate from 
colon cancer of 67% against 80% for Australia (and 71% in Denmark)71. Rectal cancer 
outcomes were similarly disparate, with UK survival at 1 year being 75% against 84% in 
Australia (Denmark 79%)71. Differences in stage at diagnosis were felt by the authors to partly 
explain the differences in outcome, especially for Denmark, where an adverse stage 
distribution contributed to comparatively low survival. Nevertheless, survival differences 
existed between nations for each stage of disease, suggesting that access to the best 
available treatment may have a greater role to play in outcome than stage at diagnosis and 
also that there may be unequal access to treatment, especially within the UK71. 
 
It would appear therefore, that there is substantial evidence that there is not only significant 
variation in reported colorectal cancer outcomes within first-world countries, but also that 
English/ UK colorectal cancer outcomes fall someway behind those of other, similar income 
level countries. The disparity in reported colorectal cancer outcomes has been the subject of 
fierce debate within the academic literature and remains on-going to this day.  
 
5.3.4. Disparity amongst reported colorectal cancer outcomes 
The EUROCARE studies, ICBP and CONCORD studies (amongst others) appear to provide 
sound evidence that the disparity within reported European colorectal cancer outcomes is real 
and that European outcomes fall behind those reported by America and Australia57,67,71. Not all 
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authors are convinced of the validity of these international outcome comparisons however, 
especially in relation to English/ UK outcomes. 
  
Poor English/ UK cancer related outcomes are frequently attributed to stage at diagnosis, 
especially as variations in survival are greatest for the first 3-12 months after diagnosis. After 
this time period, survival is much more homogenous between UK and European/ other first 
world CRC outcomes.65. Autier and Boniol use this argument as the basis for a letter 
published in the Lancet, reasoning that there are numerous other factors not associated with a 
country’s performance in treating cancer which may affect survival72. Autier and Boniol note 
that the UK has been criticised for poor administrative systems in relation to cancer 
registration (for example registration of date of recurrence rather than date of diagnosis) and a 
comparatively poor level of complete case ascertainment. They quote the case ascertainment 
of breast and colorectal cancer cases in the UK in comparison to Finland as evidence 
(Thames Cancer Registry case ascertainment 1990-2001: breast cancer 85%, colorectal 
cancer 87.8%; Finnish case ascertainment 1990-2001: breast cancer 98.5%, colorectal cancer 
98.8%), concluding that to fully understand country specific survival data, it must be looked at 
in the context of country specific incidence and mortality data72. 
 
Beral and Peto writing in the British Medical Journal then go on to argue that it is the lack of 
compulsory registration of cancer (as opposed to death, which is compulsory) within the UK, 
that is the underlying cause of the disparity in survival73. Within the UK, death certificates are 
an important tool for the identification of patients who had cancer. These cases are almost 
always excluded from survival analyses for obvious reasons but in order to limit exclusions, 
intensive searching of the medical notes for mention of cancer is undertaken. If the first 
mention found of a cancer is that of recurrence (but which is then subsequently recorded as 
the date of diagnosis), falsely short survival times are derived. Beral and Peto also argue 
unregistered survivors are frequently not included in UK cancer survival statistics (in one 
catchment areas, up to 23% of cancer survivors were unregistered), again leading to 
misleading survival figures73. 
 
In order to test the assumption that 1 year differences in survival were not linked to health 
system performance, but wholly to measurement artefact, McPherson and Brown fitted a 
crude model to the data presented by Coleman et al. for breast and colorectal cancer reported 
in the ICBP74. They then extrapolated this survival to 5 years and compared the observed (i.e. 
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Coleman et al.) with the adjusted results. UK 5-year relative survival figures for CRC were 
53.6% (observed) and 59.3% (adjusted). Danish figures were 55.8% (observed) and 58.6% 
(adjusted), whilst Swedish figures were 62.6% (observed) and 59.2% (adjusted). Using their 
model, UK survival figures from colorectal cancer were significantly better than previously 
reported. Whilst McPherson and Brown acknowledge their model is crude and has only been 
applied to a limited range of data, they argue that artefactual bias may be contributing 
substantially to the UK’s poor reported outcomes and that until these factors are considered, 
current estimates of UK survival following colorectal cancer (amongst others) may well be 
wrong74.  
 
Despite the arguments put forward by Autier and Boniol, Beral and Peto and McPhearson, the 
work of authors such as Yu et al. and Maringe et al., alongside projects such as the ICBP, 
makes it difficult not to conclude that English (UK) colorectal cancer outcomes fall behind 
those of Europe, America and Australia. Yu et al. presented data from two very closely 
matched datasets, both in size, completeness and how the data was collected. Maringe et al. 
show that stage at diagnosis only partly explains differences in outcome but also that the 
differences in outcome remained, not matter what the stage of disease. Maringe et al.’s results 
are further reinforced by those of the ICBP, where again, differences in survival were 
consistent at each stage of disease. It is likely therefore that poor English colorectal cancer 
outcomes are real and that whilst English outcomes are certainly influenced by a high number 
of patients presenting with advanced disease, other factors are likely to be contributing.  
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5.4. Emergency Colorectal Cancer  
Stage at diagnosis of any cancer, not just colorectal, has an obvious impact on likely survival, 
yet stage at diagnosis in colorectal cancer is not the only predictor of poor outcome. Patients 
who present with colorectal cancer in an emergency fashion have been shown to undergo 
longer operations, have longer admissions with more re-admissions and a higher rate of 
perioperative mortality than those who present in an elective fashion63,75,76. Thus emergency 
presentation with colorectal cancer is a stage-independent predictor of negative outcome and 
identifying factors which may predict emergency admission, offers one potential route to 
improving English colorectal cancer outcomes76.   
 
5.4.1. Patient factors which may contribute to Emergency 
Presentation 
Emergency presentation of colorectal cancer has been recognised as a persistent problem 
with English (and UK) colorectal cancer patients since the 1990’s.65,77–79 The vagaries of 
colorectal cancer symptoms, the reluctance of patients to discuss bowel habit and the fear of a 
potentially life-limiting diagnosis, contrive to make patients reluctant to present and the 
diagnosis of colorectal cancer clinically challenging80,81. 
 
Attempts to elicit factors in a patient’s history or presentation that may point to an early 
diagnosis of colorectal cancer (and in particular those most likely to present as emergencies) 
have been the subject of numerous studies82–85. Traditional ‘red ‘flag’ symptoms of CRC 
include weight loss, change in bowel habit, decreased appetite, rectal bleeding and relevant 
family history. Nevertheless, a full time GP is likely to see only 1 new case of CRC each year, 
against a multitude of abdominal pain, changes in weight and appetite and rectal bleeding86. 
Therefore, although a common disease, CRC remains an uncommon diagnosis in primary 
care. 
 
 Attempting to define those most likely to present as an emergency was the subject of a 
review by Wallace et al. 97 907 patients, presenting to primary care with CRC between 2007 
and 2011 were reviewed.  This study demonstrated that women, the socioeconomically 
deprived, those of non-white ethnic descent, those with dementia, and those with cardiac, 
neurological or liver disease were the most likely to present as an emergency87. These 
findings were confirmed by the study of Rabeneck et al. who again noted that it was women 
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and the socioeconomically deprived who were most likely to present to primary care with 
CRC; suggesting that one of the reasons women may present more frequently as an 
emergency was a sense of embarrassment about undergoing large bowel endoscopy 
performed by a male doctor88.  
 
Whilst the ‘red flag’ symptoms for CRC are well recognised by healthcare workers, Cleary et 
al. in a case control study of primary care patients, attempted to identify clinical features 
associated with emergency CRC presentation89. They noted that those most likely to present 
as emergencies were those who had abdominal pain, weight loss and/ or diarrhoea, but also 
that the majority of patients who subsequently presented with emergency CRC (63%) had 
reported symptoms of their disease at least 30 days beforehand. Cleary et al. therefore 
concluded that at least some cases of emergency presentation of CRC should be 
preventable89.  
 
Stapley et al. assessed the mortality of CRC in relation to symptom presentation and symptom 
duration in primary care, noting that rectal bleeding was associated with a less advanced 
stage at admission, but that a mild anaemia found on phlebotomy was associated with a more 
advanced stage (and therefore higher mortality)90. No relationship was found however, 
between length of symptom duration and stage at presentation or mortality90. Gunnarsson et 
al., in a review of patients presenting to one Swedish district general hospital between 1996 
and 2005, even found that emergency admission with CRC was more likely in the summer 
(July and August) than at other times of the year; they were unable however to offer a 
satisfactory answer as to why this might be91. 
 
Risk factors for emergency admission in English patients were assessed in a review by 
McPhail et al. that encompassed all colorectal cancer cases diagnosed in England between 
2006 and 200865. They found that older age and advanced stage of disease were predictive 
for emergency admission, as were but to a lesser extent, co-morbidity, lower socioeconomic 
grouping and female sex. Emergency presentation was independently associated with short-
term mortality, even after taking account of confounding variables65. The enormous effect of 
age on emergency presentation was elegantly displayed by a further study by Elliss-Brookes 
et al. looking at Routes to Diagnosis for Cancer. Whilst this study included all types of cancer, 
it notes that for those aged ≥85years, 43% of cancer diagnoses were made on emergency 
admission. 
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5.4.1.1. Figure 10: Cancer Diagnoses by Route and Age in    
England 2006-200892 
 
Screen-
detected 
(%) 
TWW 
(%) 
GP 
referral 
(%) 
Other 
outpatient 
(%) 
Inpatient 
elective 
(%) 
Emergency 
presentation 
(%) 
DCO 
(%) 
Unknown 
(%) 
n 
All 
cancers 
5 26 21 10 6 24 1 8 739 667 
 Under 
50 years 
2 29 24 10 6 15 0 13 81 072 
 Aged 
50–59 
years 
12 26 21 9 6 15 0 10 102 487 
 Aged 
60–69 
years 
10 26 22 10 6 18 0 8 181 958 
 Aged 
70–79 
years 
2 28 23 10 6 25 1 6 207 389 
 Aged 
80–84 
years 
0 25 20 9 5 34 1 6 87 940 
 Aged 
85+ years 
0 20 16 7 4 43 3 7 78 821 
*TWW: Two Week Wait, DCO: Death Certificate Only 
 
Duration of symptoms has been put forward by some authors as a possible explanatory 
variable for the high numbers of English colorectal cancer patients presenting as emergencies 
with aggressive, advanced stage disease. It has been suggested that there may be sub-
groups of disease, such as those with slow-growing tumours, who have a long duration of 
symptoms and yet a relatively early stage at diagnosis. Those with aggressive disease may 
have a shorter symptom duration and subsequently more advanced disease at 
diagnosis85,90,93,94. Symptom duration being associated with poor survival has been reported for 
over 30 years. Mulachy et al. reviewed the outcomes of 777 consecutive CRC patients 
presenting to their institution (St. Bartholomew’s, London) to assess the impact of symptom 
duration on survival, independent of other clinical and pathological factors. Long term survival 
was found to increase consistently with length of symptom duration in univariate analysis, 
whilst the addition of stage, bowel obstruction, age, sex and tumour site in multivariate 
analysis had no effect on survival85. A similar finding was noted by Jullumstrø et al. in an 
analysis of all 1263 patients presenting to Levanger hospital between 1980 and 2004 and 
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2892 patients presenting in Norway in 2004, finding that increasing symptom duration was 
associated with less advanced disease at presentation and better survival in colon cancer 
patients, although no such association was found for rectal cancer patients84. 
 
Factors most clearly associated with emergency admission in colorectal cancer, would 
therefore appear to be older age, advanced stage of disease, female sex and lower 
socioeconomic grouping. Emergency presentation with colorectal cancer may also be 
influenced by the time from first symptoms to presentation at medical services and by time 
from physician assessment to diagnosis and treatment (i.e. diagnostic delay). Traditionally, it 
has been difficult to assess the impact that factors such as diagnostic delay may have on the 
outcomes of cancer patients, especially at a population level (as the necessary infrastructure 
has not been in place). Recent advances with large, population level databases, such as the 
National Cancer Data Repository (NCDR), are powerful tools that allow researchers to track 
patient outcomes from presentation to death and to assess the influence of multiple variables 
(e.g. diagnostic delay, differing treatments, regional variation, age, sex, socioeconomic status) 
upon outcomes. The advent of such databases which are ‘searchable’ and ‘linkable’ to other 
sources of information (e.g. primary care data) opens up further routes of investigation, 
potentially highlighting key symptoms or attributes which make a diagnosis of colorectal 
cancer more likely and as such have the potential to profoundly improve outcomes for all 
cancer patients.  
 
  
44 
 
 
5.4.2. Diagnostic Delay and Emergency Presentation 
Predicting emergency presentation in some patients will always be impossible, as there will 
always be those who present with a short symptom history, due to aggressive, rapidly 
progressing disease. In others however, diagnostic delay may be a significant factor 
influencing their presentation. Diagnostic delay has been reported as being a concern in the 
identification and management of patients with CRC as far back as the 1960’s. In 1968, 
Holliday and Hardcastle reported that only 30% of patients with colon cancer presented within 
3 months of the onset of their symptoms and that for  those with rectal cancer, 25% had had 
symptoms for over 12 months prior to presentation.95 In their study, 42% of patients with colon 
cancer presented as an emergency, with the authors attributing most of the delay to 
inadequate patient examination in primary care and to patients not appreciating the 
importance of bowel symptoms. Of the delay that was attributed to hospital delay, most was 
ascribed to waiting for investigations and to poor quality barium enemas or sigmoidoscopy. 
There was a notable absence of commentary on the time taken for surgical intervention 
however.95 
 
The importance of how presentation of cancer affects outcome, and the fact that many 
patients do not follow a standard route to diagnosis, was recognised by Elliss-Brookes et al., 
who used linked data records from the National Cancer Data Repository for every patient 
diagnosed with cancer in England between 2006 and 2008 to create an algorithm allocating a 
‘routes to diagnosis’ category for each individual92. Significant variability was noted in the 
proportion of cancers diagnosed by each route. For those with colorectal cancer, two-week 
wait and GP referral constituted 27% and 20% of all diagnoses respectively, whilst the 
proportion of screen detected cancers increased from 0.1% in 2006 to 5% in 2008 (reflecting 
the roll out of the NHS Bowel Cancer Screening Program). Emergency presentations made up 
26% of all presentations but were proportionally much higher in teenagers and young adults 
(57% of all diagnoses in this age group). Emergency presentation was also, unsurprisingly, 
associated with a considerably lower one-year survival compared with those who presented 
by other routes (1 year relative survival for CRC patients: screen detected- 98%, two-week 
wait 82%, GP referral 82%, emergency presentation- 50%)92.  
 
How variation in the number of primary care consultations (for potential cancer related 
symptoms) prior to secondary care referral affects outcomes was the subject of a large study 
by Lyratzopoulos et al. 41,299 patients with 24 different cancers, who participated in the 2010 
National Cancer Experience Survey in England were assessed for the number of general 
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practitioner consultations prior to hospital referral96. Wide variation in the number of primary 
care consultations before referral was found, with younger patients, women and those from 
ethnic minorities being significantly more likely to have 3 or more consultations prior to 
referral, as were those with colon cancer in comparison to rectal cancer (OR 1.60, 95% CI 
1·36–1·87). Lyratzopoulos et al. concluded that researchers should focus on better 
understanding of cancer signs and symptoms in these groups in order to improve outcomes.96 
 
Lyratzopoulos et al. failed to account however for rapid repeat consultations to follow up 
appropriate investigations (and which are therefore not a failure to suspect the diagnosis) and 
did not record the time interval between consultations for those who attended more than once, 
and as such their study has been criticised for these reasons.96 Colorectal cancer by the 
nature of the disease, tends to have an insidious onset, and symptom recognition may be 
challenging for both the patient and clinician alike. Studies which have assessed patient/ 
clinician interaction in primary care, prior to referral to secondary care for investigation, have 
found the majority of patients to be asymptomatic prior to presentation and therefore to have 
limited opportunities for reduction in diagnostic delay, except potentially through 
screening)85,97,98. Nevertheless, what the work of Ellis-Brookes, Lyratzopoulos and others 
clearly demonstrates is that despite recent efforts, there is much variation (and therefore 
potential delay) in the way patient’s access secondary care and that if efforts to reduce 
unplanned or emergency admission for cancer in general, not just CRC, are to be reduced, 
this variability must be addressed.  
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5.4.3. Management of the Emergency Colorectal Cancer Patient 
The diagnosis of cancer and any variation in time to diagnosis represents only one component 
of a treatment pathway. Differences in management are also of crucial importance in 
determining an individual’s outcome. Whilst variation in the outcomes of colorectal cancer 
treatment worldwide are widely reported, no direct comparison has been undertaken of how 
the management of  emergency colorectal cancer patients in England compares to other 
countries with similar healthcare systems51,57,66,67,99,100. The 2011 paper of Morris et al., 
provides a 30-day postoperative mortality figure for all English colorectal cancer patients of 
6.7% and 14.9% for those undergoing emergency resection, but notes marked variability in 
treatment outcomes throughout England, even after adjustment for case-mix63. The overall 
figure of 6.7% was significantly higher than that reported in the National Bowel Cancer Audit 
(NBOCAP) report of that year (4.7%) (although Morris et al. used population level data, whilst 
the audit data was provided voluntarily) and significantly higher than that reported in 
Scandinavia, Canada and the USA (2.7% (rectal cancer alone) to 5.7%)63. Increased 
likelihood of death at 30-days was associated with elderly males, increased socioeconomic 
deprivation, increased co-morbidity, advanced stage of disease at presentation and necessity 
for urgent operative intervention63.  
 
An attempt to establish why such variation in outcomes exists in English colorectal cancer 
outcomes was undertaken by Warwick et al. through and in-depth analysis of patients treated 
in East Anglia. All cases of colorectal cancer registered with the Eastern Cancer Registry and 
Information Centre (ECRIC) between 1999 and 2005 were assessed.101 A similar distribution 
of demographic variables, stage of disease and treatment factors was found among the 
hospitals enrolled, but significant differences were obtained in the number of lymph nodes 
resected and examined, the number of patients who received a major resection and/ or 
chemotherapy and the proportion of patients with advanced disease who did not receive an 
operation. The authors concluded that there was a lack of consistency in colorectal cancer 
management in East Anglia, but that no one single factor could be found to account for this101.  
 
Other authors have suggested that, rather than variation in the initial management of a patient, 
it is in fact a clinical team’s failure to recognise and treat deterioration in a patient’s 
postoperative condition (hence failure to rescue), that is the underlying cause of variation in 
postoperative outcomes. Henneman et al. evaluated the association between structural 
hospital characteristics (i.e. volume of patients, teaching status and ICU facilities) and failure 
to rescue in Dutch colorectal cancer patients102. Of the 25, 591 patients, from 92 different 
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hospitals included within the study, average mortality was 4.3% with 23% of patients suffering 
a severe complication. Failure to rescue rates varied between 0 and 39%. Hospital type and 
hospital volume were not found to be independently associated with failure to rescue, but 
access to intensive care facilities was, with those hospitals with the lowest levels of intensive 
care support having the highest rates of failure to rescue102. England has a particularly low 
level of intensive care support in comparison to other developed nations. Germany provides 
24.6 beds per 100,000 population, the United States 20, France 9.3 and Sweden 8.7. England 
in comparison has 3.5103.  
 
Patients undergoing surgery for colorectal cancer frequently require intensive care support, 
either because of their index operation or to overcome complications. Almoudaris et al. used 
Hospital Episode Statistics (HES) data to compare rates of failure to rescue in those being 
treated for colorectal cancer in 150 English NHS Trusts. In a study encompassing 144, 542 
patients treated between 2000 and 2008, significant differences were found in the rates of 
failure to rescue between Trusts. Those in the highest mortality quintile had a 1.7 times 
greater chance of death if they required re-intervention than those in the lowest mortality 
quintile104. Although Almoudaris et al. were not able to define exactly which complications or 
interventions were most associated with likelihood of death (due to limitations in coding within 
HES), their study suggested significant differences in the management of post-operative 
complications within the English NHS.  The work of Henneman et al. and Almoudaris et al., 
alongside that of Morris et al. and Warwick et al. would suggest that, not only is there a lack of 
consistency in the management of the English colorectal cancer patients, but also variation in 
the ability of clinical teams to recognise the deteriorating patient. Combined with a relative lack 
of intensive care support, there is much scope for improvement in the management of the 
colorectal cancer patient in secondary care in England.  
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5.5. Improving Colorectal Cancer Outcomes in England and 
the United Kingdom 
In the mid-1990s the UK government became aware of the rising incidence and prevalence of 
cancer within the UK, alongside a recognition that there was inequality of access to cancer 
services, the so called ‘postcode lottery’. Since that time, there has been a sustained effort, 
both on the part of the UK government/ Department of Health and by the medical profession 
itself, through various initiatives to improve access to cancer services and overall cancer 
related outcomes. 
 
The initial response to the recognition of poor UK cancer related outcomes was to commission 
the chief medical officers of the day, Kenneth Calman (England) and Deidre Hine (Wales) to 
write a report as to how cancer services may be restructured to meet rising demand and to 
ensure that each patient received equal access to expert care. The ‘Framework for 
Commissioning Cancer Services’ report (known almost universally as the Calman-Hine report) 
was broadly accepted and implemented, and was the first in a series of reports aimed at 
continually improving UK cancer services and outcomes.  
5.5.1. The Calman-Hine Report 
The Calman-Hine report of 1995 proposed radical reform of UK cancer services, 
recommending change from a generalist model (whereby patients were treated by a general 
surgeon or physician with specialist support) to a fully specialist model105. Its recommendation 
of concentration of surgical cancer services into smaller surgical centres of excellence, 
working alongside site specialist multidisciplinary teams, was a fundamental departure from 
how services had previously been provided106. 
 
Implementation of the suggested model of care was at first sporadic, as the NHS was also 
undergoing a period of profound organisational change105. However by the mid 2000’s, the 
majority of suggested changes had been implemented with authors reporting increased use of 
multidisciplinary teams, increased adherence to guidelines and evidence of subsequent 
improved 5-year survival rates for cancer107–110.  
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5.5.2. The NHS Cancer Plan 2000 
The NHS Cancer Plan of 2000 was a direct result of the successful implementation and 
improved outcomes for cancer patients of the Calman-Hine report, but at the same time, 
recognised the continuing disparity in cancer incidence, prevalence and outcomes amongst 
different socioeconomic groups and the enduring variability in treatment delivered throughout 
the country.  It aimed, for the first time, to link prevention, diagnosis, treatment, care and 
research111. The Cancer Plan of 2000 also introduced cancer waiting time targets; 2 weeks 
from GP referral to specialist outpatient review, 31 days from decision to treat to first treatment 
and 62 days total from GP referral to first treatment111. 
 
The Cancer Plan of 2000 has received a mixed reception. Whilst some authors (Rachet et al.) 
examining English cancer outcomes in comparison to Welsh (where a cancer plan was only 
introduced in 2006) note that 1 year survival for all cancers was initially better in Wales than 
England, but that this trend was reversed when those diagnosed in 2004-6 were 
considered112. There was little difference between 3-year outcomes, with the authors 
concluding that the Cancer Plan had had a modest impact upon outcomes.  Others have 
found that cancer waiting times have had no impact on outcomes for certain cancers (Raptis 
et al.)113. In relation to colorectal cancer, the majority of studies conclude that cancer waiting 
times have had little impact on a patient’s journey time or on their survival, although some 
studies note a higher cancer detection rate, albeit at the expense of many referrals which 
failed to adhere to the guidelines112,114–117. 
 
One of the flagship policies within the Cancer Plan was the introduction of the ‘two week wait’ 
from point of referral by general practitioner to review in secondary care (from a previous 
system of urgent/ routine referrals to a named clinician). Opinions as to the effect ‘two week 
wait’ have had on cancer detection and treatment times are divided. Some authors report that 
whilst patients with cancer referred to the two week wait clinic are seen faster than standard 
referrals, they also tend to have more advanced disease in comparison to direct referrals, who 
take longer to come to treatment but have less pathologically advanced disease118,119. Quicker 
access to investigation, diagnosis and review may also be assumed to result in an improved 
patient experience. Yet is recognised that the majority of ‘two week wait’ referrals do not have 
cancer, but that in order to meet the target, patients often receive a less individualised service, 
leading to a lack of doctor/ patient interaction116. Thus the patient feels that are merely an item 
moving along a ‘production line’ to diagnosis. 
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The greatest criticism of ‘two week wait’ however, comes not from erosion of the doctor/ 
patient relationship but from the recognition that time to referral is most often not the not the 
major source of delay in a patient accessing cancer services. It is in fact the time preceding 
referral and after the appointment that are the major sources of delay120. Addressing the issue 
of time preceding referral (i.e. earlier diagnosis) has begun with the introduction of the bowel 
cancer screening program, but addressing delay in investigation and treatment requires 
significant investment in cancer services in an era of ever more stretched healthcare budgets.   
 
5.5.3. Improving Outcomes: A Cancer Strategy 
Following on from the NHS Cancer Plan 2000, the Cancer Reform Strategy was published in 
2007. This again aimed to improve outcomes but also to set the direction of development of 
NHS cancer services over the following 5 years. In particular, it recognised new opportunities 
for prevention, early diagnosis and better treatments that had become available through 
greater scientific understanding of cancer121. The Cancer Reform Strategy subsequently led to 
the publication of the Improving Outcomes: A Strategy for Cancer report in 2011122. This set 
out the coalition government’s ambition to improve cancer outcomes (primarily through earlier 
diagnosis), whilst dealing with the continuing rising incidence and prevalence of cancer, 
inequality and suboptimal care, the slow diffusion of new technologies and managing the 
rising costs of cancer care122.  
 
Whilst it is currently too early to assess the impact of Improving Outcomes: A Strategy for 
Cancer, the report will have been implemented during a period of unprecedented reform and 
change within the NHS. Cancer care is becoming ever more expensive, with rising numbers of 
people both surviving and living with the disease. Delivery of cancer care to an ageing 
population, in the face of continuing scientific advancement, will remain a persistent challenge 
for both government ministers and clinicians.  
 
5.5.4. The National Institute for Health and Care Excellence 
The National Institute for Clinical Excellence (NICE) was set up in 1999 as a body 
independent of government to provide guidance as to how to reduce variation in the 
availability and quality of NHS treatment and care. It was subsequently merged with the 
Health Development Agency in 2005 to create the National Institute for Health and Clinical 
Excellence and has a mandate to set quality standards and indicators for NHS care and to 
51 
 
 
provide guidance on standards of care, the clinical management of patients and the use of 
novel technologies and medicines. In 2011, NICE published guidelines on the diagnosis and 
management of colorectal cancer (CG131). This was updated in December 2014 and 
currently represents the most up-to-date guidance on the management of CRC in the UK39. 
Full discussion of the guidelines is beyond the scope of this literature review, but is available 
at https://www.nice.org.uk/guidance/cg131.  
 
5.5.5. Screening for Colorectal Cancer 
Colorectal cancer, with its long pre-malignant course and ~5% lifetime risk makes it a suitable 
candidate for screening. The most widespread screening method in use throughout Europe is 
Faecal Occult Blood Testing (FOBT), although a pilot study for screening with flexible 
sigmoidoscopy has been rolled out in 6 areas of the United Kingdom since March 20138,123,124. 
FOBT relies on the tendency of adenomas and malignant lesions within the colorectum to 
bleed and the peroxidase activity of haem to be detected on guaiac impregnated card.8 The 
Minnesota Colon Cancer Study showed a reduction in mortality from colorectal cancer by 33% 
with annual FOBT screening, whilst the English Bowel Cancer Screening Pilot study evaluated 
480,250 individuals for colorectal cancer using FOBT with a 56.8% uptake and a positive test 
rate of 1.9%. 1.62 cancers were detected per 1000 individuals screened with a positive 
predictive value of 10.9% for malignancy and 35.0% for adenomas.8  
 
As a result of the English Bowel Cancer Screening Pilot study, the NHS Bowel Cancer 
Screening Programme was introduced in 2006 with full roll out achieved in 2009. Currently all 
individuals over the age of 55 are invited to participate in a one off bowel scope screening test 
if offered in their area, or all individuals over the age of 60 (nationally) are offered FOBT 
testing. Recent estimates suggest that by October 2008, 2.1 million invitations to participate 
will have been sent out, with a predicted response rate of 49.6% in men and 54.4% in 
women125. Of the 1.08 million tests returned so far, 2.5% men and 1.5% of women had an 
abnormal test result. Very much in line with the trials and pilot studies, malignancy was 
discovered in 11.6% men and 7.8% of women with a positive FOBT. High risk adenomas were 
found in 43% and 29% respectively with 71% of tumours identified being classified as 
‘early’.125 
 
In relation to emergency admissions, increasing evidence is being published that screening 
has had a marked effect on the number of emergency presentations, the requirement for 
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emergency operation, 30 day mortality and rates of stoma formation126,127. Scholefield et al. 
reviewed the outcome of 150,000 individuals who were offered FOBT screening in Nottingham 
beginning in 1981. Of those invited, 60% responded and of the 1962 who had a colorectal 
cancer over the study period, 23.9% presented as an emergency. Those who engaged with 
screening had a significantly lower rate of emergency presentation, 30-day post-operative 
mortality and stoma formation. Conversely, those who had declined screening (i.e. non-
responders) had a significantly higher rate of emergency admission and stoma formation.127 
 
The findings of a study by Goodyear et al. comparing rates of emergency admission and 
outcomes before and after the introduction of a colorectal cancer screening programme in 
North Warwickshire re-iterated the findings of Scholefield et al. Goodyear et al. found that 
when rates of emergency admission were compared in 1999 (the year before screening was 
introduced) with those at the end of the study period (2004), rates of emergency admission 
had halved from 29.4% to 15.8%.83 A similar decrease was seen in the number of emergency 
procedures performed and their mortality. The absolute number of advanced (Dukes’ C or 
above) tumours presenting as an emergency halved over the study period, although as a 
proportion of emergency admissions, numbers of advanced tumours remained static127.  
 
Both the studies by Goodyear et al. and Scholefield et al. provide compelling evidence that a 
well-executed screening programme can have a marked effect on both the numbers of 
emergency presentations and their outcomes. Other endeavours to prompt early diagnosis 
include the National Awareness and Early Diagnosis Initiative (NAEDI). NAEDI was formally 
launched in 2008 and is a partnership between public (Department of Health, National Cancer 
Action Team, Cancer Research UK) and third sector organisations to support activities and 
research which lead to the earlier diagnosis of cancer. Despite this, the most recent National 
Bowel Cancer Audit Project report states that for colorectal cancer, emergency admissions 
remain a significant problem at ‘around 20%’ of all cases diagnosed in England.27 These 
efforts are laudable and steps have clearly have been taken to attempt to reduce the UK’s 
high emergency admission and early mortality rate, however it is likely that their effects will 
take several years to ‘filter through.’ 
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5.5.6. Audit of Colorectal Cancer Outcomes: The National Bowel 
Cancer Audit Program 
Recognition of the increased mortality from CRC in comparison to other developed nations 
and that national standards of care were not being uniformly met prompted the development 
of the National Bowel Cancer Audit Program (NBOCAP). The first NBOCAP report was 
produced in 2006 and it represents the most up-to-date ‘snapshot’ of colorectal cancer care 
throughout England and Wales available128. NBOCAP is run jointly by the NHS Digital and the 
Association of Coloproctology of Great Britain and Ireland (ACPGBI) and aims to improve the 
quality of care and survival of those with colorectal cancer43.  
 
The most up-to-date report is the 2017 report, publishing data regarding those treated for 
colorectal cancer in England and Wales between 2015 and 2016. Case ascertainment for this 
period was 95% (of the 30 710 patients diagnosed with CRC). Mortality for all those 
undergoing surgical resection has fallen consistently since the audit began and now stands at 
3.2% (at 90 days). Emergency admission remains stubbornly high at 21% of admissions, with 
emergency or urgent major surgery being associated with a mortality of 10.3% at 90 days. 1 in 
4 colorectal cancer patients will not undergo a procedure with curative intent, although this 
comprises a complex group of the old and frail, those with early stage disease (who may only 
require endoscopic excision of a polyp cancer) and those with advanced disease43. 
 
Wide variations in length of stay, use of laparoscopic surgery, those chosen for surgical 
resection and 2-year survival are seen across Strategic Clinical Networks (the organisations 
tasked with providing and commissioning, amongst other things, cancer services across the 
English NHS). 2-year survival for the 78,609 patients treated for CRC between 1st April 2008 
and 31st March 2011 was 67%, with 80% surviving for 2 years if undergoing surgical resection, 
but only 43% surviving 2 years if no resection was undertaken43. Information regarding use of 
neoadjuvant therapy was too incomplete to be meaningful43. Identifying reasons underlying 
variability in who is selected for surgery, use of neoadjuvant therapies and rates of survival are 
the challenges that the NBOCAP audit team now face. 
 
5.5.7. Routine Datasets and ‘Big Data’ 
The term ‘big data’ is a relatively new one, coined to cover the collection and analysis routine 
data at a population level relating to anything from health, to the sales of goods, to changes in 
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demographic trends. The collection and use of routine data in cancer however is not new, and 
has been taking place in most advanced healthcare systems for many years. Over recent 
years, a ‘step change’ in relation to the collection and use of routinely collected datasets has 
taken place, facilitated mainly by developments in technology.   
 
The publication of the Calman-Hine report, with the subsequent restructuring of cancer 
services and the development of cancer networks in the mid-1990s, created an opportunity 
within the NHS for routine data on cancer to be collected and brought together in a systematic 
manner for the first time. With the advent of accurate, searchable and analysable population 
level data relating to cancer, the realisation occurred that ‘big data’ represented a new and 
previously untapped source of information, whereby at risk individuals may be identified and 
the outcomes of treatments or changes in management assessed at a population level.  
 
Currently, responsibility for the collation of routine cancer data within the English NHS lies with 
the National Cancer Registration and Analysis Service (NCRAS), itself a part of Public Health 
England (PHE). NCRAS was preceded by the National Cancer Intelligence Network (NCIN), 
which was formed in 2008 with the aim of offering an efficient and effective method of cancer 
related data collection, acting as a national repository for cancer datasets, informing and 
supporting audit and research in the English NHS and exploiting and driving improvements in 
cancer care. NCIN was subsequently merged with the cancer registration service in 2016, 
creating NCRAS129. 
 
As part of the then NCIN, the Northern and Yorkshire Cancer Registration and Intelligence 
Service (NYCRIS, now itself amalgamated into PHE) was fundamental in the creation of the 
National Cancer Data Repository (NCDR). The NCDR acts as a national cancer database 
which links data from cancer registries with that of the Hospital Episode Statistics (HES) data, 
to create an extensively cleaned database which may be used for the analysis of surgical 
procedures, mortality and workload in relation to cancer patients in England and Wales. Like 
all ‘big data’ databases, the NCDR suffers from limitations (data quality, inconsistency and 
instability, challenges regarding validation of data and it’s analysis). Nevertheless, the NCDR 
at the time of its inception was regarded as a model database for cancer, allowing for the 
exploitation of comprehensive, population level datasets for the improvement of cancer 
services and outcomes. It is from the NCDR that the data underpinning this thesis was drawn.   
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5.6. Summary 
The weight of evidence suggesting that colorectal cancer outcomes in England are behind 
those of similar income level European countries and substantially behind those of America 
and Australia is overwhelming57,60,67,71. England appears to have high numbers of patients 
presenting as emergencies with rapidly fatal disease, but also wide variations in patient 
management and outcome, particularly in the early stages of treatment58,62,63,101,104. To 
improve English colorectal cancer outcomes, patients must be identified earlier, prevented 
from presenting as an emergency, be (if possible) made fit enough to undergo major surgery 
and, should they deteriorate through the course of their treatment, have that deterioration 
recognised and acted upon before it is too late to ‘rescue’ them. Cancer plans and increased 
availability of critical care beds will partially assist in this aim, but the key to improved 
outcomes will remain earlier diagnosis and more consistent treatment.  
 
‘Big data’ in the form of the NCDR and other large datasets allows researchers to assess the 
impact interventions have on cancer care and to compare our standards of care with others, 
but also to identify those patients who are most likely to benefit from any particular 
intervention. This project aims to reflect on, quantify and compare recent colorectal cancer 
care in England and to highlight where efforts may best be spent in order to bring about the 
greatest possible improvement in colorectal cancer related outcomes.  
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6. Aims and Objectives 
6.1. Aims 
Whilst there is no doubt that outcomes for all patients with colorectal cancer (within the 
developed world at least) have improved considerably over the last 40 years, outcomes for 
English colorectal cancer patients are consistently reported as less favourable than those of 
Europe, the United States and Oceania.  
Reasons why English colorectal cancer outcomes remain poor are uncertain, with seemingly 
high numbers of emergency patients with aggressive disease. These outcomes however, are 
often based on data from before the introduction of major structural changes to the English 
NHS and its reorganisation of cancer services. Further, England enjoys comparatively 
accurate and complete datasets in relation to other countries. Questions arise therefore as to 
whether English outcomes are truly as poor as described and to the extent of any 
improvement of those outcomes over recent years. 
This body of work therefore, aims to evaluate through use of population and local level data, 
whether outcomes for English colorectal cancer patients have improved and to document the 
changing face of English colorectal cancer. It hypothesises that through exploring the differing 
outcomes for elective and emergency colorectal cancer patients within the English NHS, 
previous international comparisons of poor outcomes may not be a true reflection of English 
colorectal cancer care. 
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6.2. Objectives 
1. To demonstrate how population level databases may be used to inform colorectal 
cancer practice. 
 
2. To observe differences in the demographics of English elective and emergency 
colorectal cancer patients, demonstrating how the outcome for each method of 
admission varies. 
 
3. To investigate the short-term outcomes of elective and emergency surgery in English 
colorectal cancer patients. 
 
4. To demonstrate how English colorectal cancer outcomes (both elective and 
emergency) have changed over the study period and how the introduction of the NHS 
Bowel Cancer Screening Program and novel technologies such as laparoscopic 
surgery have affected outcomes. 
 
5. To investigate the effect on outcomes of colorectal cancer patients of Self-Expanding 
Metal Stents (SEMS) when used as a ‘bridge to surgery’ and to compare those 
outcomes to those of patients who received a defunctioning stoma as their ‘bridge to 
surgery’. 
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7. Study Design, Study Period, Data Sources and Patient 
Identification 
7.1. Study Design 
This project comprises a retrospective, observational, cohort study of English colorectal 
cancer patients diagnosed and treated within the English NHS between 1998 and 2010; this 
being the most up to date data available at the time this project was undertaken. 
The data analysis and statistical package Stata (Version 13.1, 4905 Lakeway Drive 
College Station, Texas 77845-4512, USA) is used throughout to create statistical models to 
assess the outcomes of care.  
 
7.2. Study Period 
The research work for this thesis was undertaken between August 2012 and July 2014. All 
patients diagnosed and registered with colorectal cancer between 1st January 1998 and 31st 
December 2010 within the English NHS were included in the study. 1998-2010 was chosen as 
the most up to date data set available for which complete outcome and follow-up information 
was available at that time. 
 
7.3. Ethical Approval 
Section 251 and National Information Governance Board requirements for this study are 
satisfied by the East of Scotland Research Ethics Service approval (no. 08/SO501/66) given 
to Professor Eva Morris (Principal Research Fellow, Cancer Epidemiology Group, Division of 
Epidemiology & Biostatistics, Leeds Institute of Cancer and Pathology) for the data linkage 
and analysis of datasets for research into colorectal cancer. This permission allows for the 
analysis of population level datasets to be carried out under Professor Morris’ supervision, as 
was the case here. 
 
7.4. Data Sources, Data Cleaning and Patient Identification 
Data for this project were drawn from the National Cancer Data Repository (NCDR). The 
NCDR is an amalgamation of Cancer Registry, Hospital Episode Statistics Data (HES), 
National Bowel Cancer Audit Program data and death data drawn from the Office for National 
Statistics (ONS). Linkage of these data creates a complete dataset that covers the entirety of 
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a patient’s treatment pathway from diagnosis to death. The NCDR provides a comprehensive 
dataset on all individuals diagnosed with a malignant neoplasm in England between 1990 and 
2010 and is part of Public Health England (PHE). 
 
Cancer Registry data provide basic demographic, diagnostic (including pathological staging), 
treatment and death data on all individuals diagnosed with cancer within the United Kingdom. 
HES data provide detailed records of demographic, geographic, diagnostic, clinical and 
administrative data for all admissions, outpatient appointments and A&E attendances at NHS 
hospitals within England back to the financial year 1989-90. National Bowel Cancer Audit 
Project (NBOCAP) data provide demographic, diagnostic and staging data, case mix data of 
individual Trusts, hospitals and surgeons, details regarding grade of operating surgeon and 
operative urgency and clinical outcomes. ONS death data cover the date, place and cause of 
all deaths within England and Wales and supplement the data provided by Cancer Registries 
and HES. 
 
Thus the author was provided with a ‘cut’ of data from the NCDR in order to undertake this 
study. Data processing and analysis was undertaken as set out below. Support and guidance 
in relation to data processing and analysis was provided by Professor Morris and her team, 
but was performed independently by the author. 
 
Pooled cancer registry data from the NCDR were de-duplicated under World Health 
Organisation/ International Association of Cancer Registries rules (as tumours may be 
identified by more than one registry). This dataset was then linked to an extract of HES (using 
all or a combination of NHS number, date of birth and postcode at diagnosis) that included any 
individual who presented to an NHS hospital with a diagnostic code for cancer between April 
1997 and March 2010.  
 
This ‘cut’ of data was then loaded into Stata™ and command syntax written to clean, validate 
and risk adjust the data in the following manner. As anomalies became apparent within the 
data, fresh ‘cuts’ of data were requested and the command syntax re-written, until such time 
as a ‘clean’ dataset was achieved. 
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Information on all individuals over the age of 15 years (the cut-off age between paediatric and 
adult services) who had a diagnosis of colorectal cancer (ICD10130 C18-C20) were identified 
and those patients <15 years of age or who did not have a diagnosis of colorectal cancer were 
excluded from the dataset. Information on age, sex, Dukes’ stage at diagnosis and, where 
relevant, date of death was extracted from the cancer repository data.  
 
Management information and outcome data for each individual were extracted from HES with 
a primary procedure being sought for every individual identified in both the cancer registry and 
HES datasets (the linked dataset). Major resections (as defined by appropriate OPCS 
Classification of Intervention and Procedures codes (version 4) for major colorectal resection) 
were identified for all linked patients up to a month prior to, and up to 12 months after, 
diagnosis. For those undergoing two or more colorectal resections in different episodes of 
care the first procedure was taken as their major resection. For those undergoing two or more 
resections in the same episode of care the most radical procedure was used. If no major 
resection could be found the dataset was searched again in the order of minor resection, 
bypass and formation of stoma. If no operative procedure was identified then episodes of care 
which included placement of a stent were searched for. If an individual linked to HES but no 
information on intervention could be found these individuals were allocated to a ‘No surgical 
treatment within the NHS’ category. If an individual did not link to HES (as they were managed 
entirely in the independent sector or died before receiving any treatment), they were allocated 
to a separate category and subsequently excluded from the dataset. 
 
Laparoscopic procedures were identified as those major resections with accompanying 
OPCS-4 codes indicating a minimal access approach to the abdominal cavity (Y75), other 
specified approach to abdominal cavity (Y508) or endoscopic resection of lesion of peritoneum 
(T421, T428 or T429).  Converted laparoscopic operations were identified as those major 
resections with an accompanying OPCS-4 code indicating a failed minimal access approach 
(Y714).  If information on the approach to surgery was not present for an individual in the HES 
data within the NCDR, but was available in the NBOCAP dataset, then these data were used 
instead. 
 
Each patient identified was assessed for their age (at diagnosis), site of disease, Dukes’ stage 
of disease, Charlson co-morbidity score, score in relation to indices of deprivation, their index 
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admission and length of stay and, if they underwent a procedure, their post-procedural 
mortality. 
Site was assessed by ICD-10 classification as set out in Table 1 below: 
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7.4.1. Table 1: ICD-10 Code and Tumour Site 
ICD-10 Code Tumour Site 
C18 Caecum 
C18.1 Appendix 
C18.2 Ascending Colon 
C18.3 Hepatic Flexure 
C18.4 Transverse Colon 
C18.5 Splenic Flexure 
C18.6 Descending Colon 
C18.7 Sigmoid Colon 
C18.8 Colon- overlapping 
C18.9 Colon- unspecified 
C19 Rectosigmoid Junction 
C20 Rectum 
Codes C18-C18.9 were amalgamated and classified as ‘colon’ cancer, code C19 as cancer of 
the rectosigmoid junction and code C20 as ‘rectal’ cancer. 
 
Cancer Registry data contain multiple different fields of staging (e.g. clinical, pathological and 
integrated TNM, Dukes’) (described as ‘string’ data in Stata™). To allocate each tumour, and 
therefore patient, a stage at diagnosis, command syntax was written for Stata™ that removed 
invalid entries within TNM fields before converting them to equivalent Dukes’ stages. Dukes 
stage was chosen as the primary descriptor of a patient’s disease stage as it neatly 
encompasses a tumours local spread, nodal and metastatic status. If multiple Dukes’ stages 
were recorded, the highest stage was retained. If no pathological stage was recorded, then 
clinical stage was used. If there was any evidence of nodal or metastatic disease the stage 
was upgraded to Dukes’ C or D as appropriate. If no staging information at all was available 
within the NCDR, but was available within NBOCAP data, then the NBOCAP stage was used. 
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A Charlson co-morbidity score was calculated for each individual based on diagnostic codes 
(excluding cancer) for any hospital admission in the year preceding diagnosis. The cancer 
component of the Charlson index was derived from the cancer registry data within the NCDR. 
Patients were grouped into Charlson score categories of 0, 1, 2 and ≥3; higher scores 
indicating greater co-morbid disease.   
 
Admission method was defined as elective if the patient was admitted from a waiting list or 
had a booked or planned admission date. Emergency admission was defined as admission 
through the emergency department, transfer from any other acute specialty (following an 
emergency admission to that specialty), via the GP following request for immediate admission 
or any other unplanned admission. Throughout this work, ‘emergency’ or ‘elective’ refers to a 
patient’s admission status and not their CEPOD status on an operating list.  
 
Post-procedural mortality was defined as the 30-day mortality from the date of primary 
procedure. For completeness, 90-day post-procedural mortality was also calculated. Survival 
time was calculated from date of diagnosis to date of death or when censored (30th June 
2010). For those individuals whose primary procedure preceded the date of diagnosis, the 
primary procedure was taken as the date of diagnosis. 
 
7.5. Exclusions from the Dataset 
Any patient who did not match did not have an index admission method, did not match to a 
cancer team or did not match to HES was excluded from analysis. It was impossible to 
decipher the reasons underlying why these patients did not link and therefore accurate dates 
of admission, diagnosis and treatment were not available for these individuals. Those 
individuals identified as having duplicate records within the dataset had their duplicate record 
removed.  
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7.5.1. Diagram of study patient inclusion and exclusion 
 
 
 
 
 
  
382,815 
Individuals identified with a first, primary diagnosis 
of colorectal cancer between 1st January 1998 and 
31st December 2010 within the NCDR 
Excluded (n= 28,923) 
 No index admission (n= 27,071) 
 No cancer team (n= 1852) 
353,892 
Individuals formed the final dataset 
248,655 
Elective Admissions 
105,237 
Emergency Admissions 
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8. Demographics of Elective and Emergency Colorectal Cancer 
Patients 
8.1. Demography of Elective and Emergency Colorectal Cancer 
Patients 
Colorectal cancer in England/ the United Kingdom has a marked North/South divide, with a 
higher incidence of disease recorded in Scotland, Northern Ireland and the North of England, 
whilst the picture in the remainder is much less clear, with isolated areas of high incidence and 
prevalence within the east and south west2.  
 
Socioeconomic deprivation throughout the United Kingdom (like all countries) is mixed, but it 
is generally accepted that again, a North/ South divide exists (with greater socioeconomic 
deprivation in the North)131. Socioeconomic deprivation in relation to cancer has been shown 
to be predictive, not only of delay in diagnosis, but also of poor outcome after treatment132–135. 
Emergency presentation is recognised as being associated with a significantly worse 
prognosis compared to elective presentation and is associated, along with socioeconomic 
deprivation, with increasing age, female sex and number of co-morbid conditions88,136–138.  
 
Both the United Kingdom and Denmark are recognised as having inferior outcomes in relation 
to colorectal cancer compared to equivalent income level countries100. Both countries have 
broadly similar population demographics, alongside broadly similar expenditure on healthcare. 
Recent years have seen a significant improvement in Danish colorectal cancer outcomes, 
which has been attributed to a focus on expeditious diagnosis and a reduction in treatment 
delay (and therefore reduced numbers of emergency presentation)139.  
 
Attempting to reduce the numbers of those who present as an emergency with colorectal 
cancer has also been a key part of recent efforts to improve colorectal cancer outcomes in 
England/ the United Kingdom, particularly through the recent introduction of the NHS Bowel 
Cancer Screening Program (NHSBCSP)111,124. Given the link between socioeconomic 
deprivation, co-morbidity etc. and the likelihood of unplanned admission, establishing 
demographic factors which may place an individual at higher risk of emergency presentation, 
how risk of emergency presentation varies throughout England and how programs such as the 
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NHSBCSP affect likelihood of emergency presentation are essential in evaluating current 
interventions and in understanding where and to whom further efforts should be targeted. 
 
Thus, this chapter aims to display crude demographic data for patients diagnosed with 
colorectal cancer within the English NHS between 1998 and 2010, how presentation of 
patients with emergency colorectal cancer varies throughout England by volume of work (of 
NHS Trusts) and how numbers of emergency admissions have been influenced since the 
introduction of the NHSBCSP. Logistic regression will be used to demonstrate those variables 
most associated with emergency admission and to demonstrate the likelihood of admission by 
NHS Trust.  
 
Logistic regression is the statistical process used to analyse a dataset in order to take account 
of the effect of independent variables (e.g. age, sex, co-morbidity) on a dichotomous (i.e. 
binary) dependent variable (e.g. emergency/ elective admission).  In doing so, logistic 
regression accounts for the impact of explanatory variables on an outcome of interest and 
obtains the odds ratio for that outcome (i.e. the likelihood of that outcome occurring, given the 
presence of the independent variables). Once a dataset has been analysed by logistic 
regression, it may be considered ‘risk adjusted’. 
 
The advantage of logistic regression is that it does not require either the dependent or 
independent variables to be normally distributed, nor to have equal variance, thus avoiding 
confounding effects. Logistic regression was chosen for data analysis for this dataset as it 
provides clear evidence of the effect of multiple independent variables on the outcome of 
interest (e.g. effect of being male, elderly with multiple co-morbidities on likelihood of 
emergency admission with colorectal cancer).  
 
Logistic regression does suffer from limitations however. Whilst excellent for the analysis of 
categorical outcomes, it is not appropriate for the analysis of continuous outcomes (e.g. length 
of stay). It is also very dependent on the identification of all relevant variables (e.g. given that 
colorectal cancer is, usually, a disease of the elderly, age of patient is a key variable; to not 
include age would much reduce the validity of any results). Those variables must also be 
independent of each other. If the variables are linked (e.g. if all patients chosen for analysis 
are known to carry a certain genetic mutation for aggressive disease) then logistic regression 
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overstates the significance of observations and can be vulnerable to overconfidence in its 
predictions.  
 
Efforts were made to ensure that the dataset used for this project was ‘cleaned’ thoroughly 
and key variables for inclusion were identified by review of the literature prior to analysis. It 
was anticipated that use of key variables, with similar methods of analysis would also allow for 
easier comparison between results, with (again) a reduced chance of confounding errors.  
 
8.2. Methodology and Statistical Modelling 
Patients diagnosed with colorectal cancer between 1st January 1998 and 31st December 2010 
were identified from the NCDR database. Each patient identified was assessed for their age 
(at diagnosis), year of diagnosis, site of disease, Dukes’ stage of disease, Charlson co-
morbidity score, level of socioeconomic deprivation (IMD income category) and their index 
admission status (i.e. elective or emergency). Ethnicity was not included as there were 
numerous patients with missing or duplicate data, such that any conclusions drawn would 
have been unreliable. 
 
Univariate analysis was used to produce unadjusted odds ratios for each variable relating to 
likelihood of emergency admission (i.e. the effect that variable alone had on the prospect of 
emergency admission). Multiple logistic regression analysis (i.e. the effect a variable has on 
the outcome of interest, taking into consideration multiple other variables, all of which also 
influence the outcome of interest) was used to investigate associations between each 
independent variable and risk of emergency admission; this was performed using the 
xtmelogit function within StataTM Version 13.1. Variables adjusted for in this case included 
likelihood of emergency admission sex, age, site of disease, Dukes’ stage at diagnosis, IMD 
income category, Charlson co-morbidity score and year of diagnosis. Two hospitals Trusts 
(The Christie and Royal Marsden) were excluded from both the univariate and logistic 
regression analyses (although were included in the presentation of the crude data), as each 
Trust provides supra-specialist services in relation to colorectal cancer treatment, and 
therefore has very few emergency admissions. Inclusion of these Trusts would have falsely 
skewed any results. Statistical significance was set at p≤0.05.  
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Funnel plots were drawn using the Stata command funnelcompar to compare rates of 
emergency admission by NHS Trust and rate of emergency admission against volume of 
work. A funnel plot is a diagrammatic representation of the size of effect of the outcome of 
interest measured against each study’s (or in this case institution’s) size or precision140. A 
funnel plot provides clear visual evidence of expected variation in outcome whilst also 
displaying divergent performance. Like all statistical methods, it suffers from disadvantages, 
mainly in that choice of outcome and metric of interest can markedly affect the appearance of 
the plot. Nevertheless, with carefully selected data, funnel plots represent an excellent method 
for the detection of outlying performance in a simple, graphical manner.  
 
Funnel plots were drawn for both unadjusted and risk adjusted rates of emergency admission 
(against volume of work). Risk adjusted rates included adjustment for age, sex, site of 
disease, Dukes’ stage, Charlson co-morbidity score and IMD category.  
 
8.3. Results 
8.3.1. Crude Demographic Data 
382,815 individuals were identified within the NCDR as having a first, primary diagnosis of 
colorectal cancer between 1st January 1998 and 31st December 2010. Of these 28,993 either 
had no index admission or failed to match to HES and so were excluded, leaving a total of 
353,892 cases which formed the final dataset.  Within this final data set 105,237 were 
emergency admissions (29.7%). 
 
Presentation of the crude demographic data is set out in Table 2. The overall proportion of 
patient admitted as an emergency fell over the study period from 32.6% admissions in 1998 to 
25.3% in 2010, with more women than men presenting as emergencies (26.8% of men, 33.3% 
of women). 
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8.3.1.1. Table 2: Crude Patient Characteristics 1998-2010 
Crude Patient Characteristics 
  
Elective Admissions 
Emergency 
Admissions 
Total 
n % n % n 
Sex 
Male 142,288 73.2 52,205 26.8 194,493 
Female 106,367 66.7 53,032 33.3 159,399 
Age 
≤60 47565 75.1 15,788 24.9 63,353 
61-70 69586 77.3 20,381 22.7 89,967 
71-80 85518 71.5 34,157 28.5 119,675 
>80 45986 56.8 34,911 43.2 80,897 
Site 
Colon 140,354 62.8 83,136 37.2 223,490 
Rectosigmoid 21,455 76.1 6,724 23.9 28,179 
Rectum 86,846 85.0 15,377 15.0 102,223 
Dukes’ 
Stage 
A 31,973 94.0 2,055 6.0 34,028 
B 66,521 76.1 20,944 23.9 87,465 
C 63,841 72.8 23,902 27.2 87,743 
D 29,338 55.8 23,238 44.2 52,576 
Unknown 56,982 61.9 35,098 38.1 92,080 
Charlson 
Co-
Morbidity 
Score 
0 199,855 74.1 69,964 25.9 269,819 
1 32,176 60.4 21,087 39.6 53,263 
2 10,855 56.6 8,337 43.4 19,192 
≥3 5,769 49.7 5,849 50.3 11,618 
IMD 
Income 
Category 
Most Affluent 
(1) 
51,479 74.1 17,984 25.9 69,463 
2 55,415 72.4 21,129 27.6 76,544 
3 53,396 70.5 22,366 29.5 75,762 
4 48,365 68.4 22,372 31.6 70,737 
Least Affluent 
(5) 
40,000 65.2 21,386 34.8 61,386 
Year of 
diagnosis 
1998 16,167 67.4 7,832 32.6 23,999 
1999 16,653 67.7 7,946 32.3 24,599 
2000 17,004 67.8 8,068 32.2 25,072 
2001 16,392 67.0 8,078 33.0 24,470 
2002 16,553 67.1 8,132 32.9 24,685 
2003 17,863 68.7 8,129 31.3 25,992 
2004 18,540 68.3 8,623 31.7 27,163 
2005 19,436 69.9 8,389 30.1 27,825 
2006 20,533 71.9 8,030 28.1 28,563 
2007 21,254 73.0 7,866 27.0 29,120 
2008 22,240 73.2 8,138 26.8 30,378 
2009 22,791 73.7 8,150 26.3 30,941 
2010 23,229 74.7 7,856 25.3 31,085 
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Age was associated with a higher proportion of emergency presentations at the upper and 
lower ends of the age spectrum, with those aged ≤20 years and >80 years both having 
markedly higher percentages of patients presenting as an emergency. From age 21 years 
onwards, elective admission steadily rose (and emergency admission fell), before 70 years of 
age, after which emergency admission rose and elective admission fell (Figure 11). 
 
8.3.1.2. Figure 11: Age by Admission Method 
 
 
The highest proportion of elective admissions by site of disease was in rectal cancer patients 
(85.0%), whilst those with colon cancer made up the greatest proportion of those presenting 
as an emergency (37.2%). Few patients presented as an emergency with Dukes’ A disease 
(6.0%), whilst those with Dukes’ D disease were roughly equally split between elective 
(55.8%) and emergency presentation (44.2%) (Figure 12).  
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8.3.1.3. Figure 12: Dukes’ Stage by Admission Method 
 
 
 
A higher proportion of those with a greater numbers of co-morbidities presented as an 
emergency (Charlson score ≥3, emergency admission 50.3%) compared to those with fewer 
co-morbidities (Charlson score 0, emergency admission 25.9%). Greater socioeconomic 
deprivation was also associated with a greater likelihood of emergency admission (25.9% of 
those in IMD income category 1 admitted as an emergency vs. 34.8% of those in category 5). 
The proportion of patients admitted as an emergency fell over the study period from 32.6% of 
total admissions in 1998 to 25.3% in 2010.  
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8.4. Impact of Screening on Emergency Admission 
The majority of patients included in this study developed and were treated for their cancer 
before the NHSBCSP began in 2006. Table 3 however, clearly displays the impact that the 
NHSBCSP had on emergency presentation.  
8.4.1. Table 3: Screening Status by Admission Method 
Screening Status by Admission Method 
 Elective Emergency Total 
 n % n % n 
Precedes BCSP start 148,921 68.3 69,263 31.7 218,184 
Screen-detected 7,346 98.0 150 2.0 7,496 
Interval Diagnosis 3,456 79.2 905 20.8 4,361 
Non-participant 6,361 75.4 2,070 24.6 8,431 
Never invited (<60) 15,905 76.4 4,918 23.6 20,823 
Never invited (60-74) 27,845 77.5 8,090 22.5 35,935 
Never invited (>74) 38,821 66.2 19,841 33.8 58,662 
Total 248,655  105,237  353,892 
 
Those who were invited to participate in the NHSBCSP and were found to have CRC had a 
very low rate of emergency admission (2%) compared with those who were invited but did not 
participate (24.6%). Further, the proportion of Dukes’ A tumours in those who participated in 
screening was significantly greater compared with those who did not (Dukes’ A 27.7% 
tumours screen detected, 10.3% non-participant, Chi2  p= <0.001). The reverse was true for 
those with Dukes’ D tumours (Dukes’ D 6.3% tumours screen detected, 21.2% non-
participant, Chi2  p= <0.001). 
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8.5. Volume of Work and Rate of Emergency Admission by NHS 
Trust 
After exclusion of the two Trusts who undertake supra-specialist work, 147 NHS hospital 
Trusts were included for analysis (352,337 individuals; 247,197 (70.2%) elective admissions 
and 105,140 (29.8%) emergency admissions). The Trust with the greatest volume of work 
admitted 5,523 patients over the study period; of these 3,914 (70.9%) were elective 
admissions and 1,609 (29.1%) were emergency admissions. The median number of 
admissions for all Trusts was 2,192 (IQR 1,298). The median number of elective admissions 
was 1546 (IQR 959) and emergency admissions 654 (IQR 435). 
 
In terms of crude data, the Trust with the highest proportion of elective admissions admitted 
79.6% (1,196 patients) electively. In comparison, the Trust with the lowest proportion of 
elective admissions and therefore the highest number of emergency admissions, admitted 
59.3% (391 patients) electively and 40.7% (268 patients) as an emergency (total 659 
patients). This Trust was also the Trust with the lowest volume of work undertaken over the 
study period.  
 
Rates of unadjusted and adjusted emergency admissions (by sex, age, stage of disease, site 
of disease, socioeconomic deprivation, co-morbidity and year of diagnosis) are presented in 
Figures 13 and 14 below.   
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8.5.1  Figure 13: Unadjusted Rate of Emergency Admission by NHS 
Trust* 
 
*Red lines indicate overall emergency admission rate; dashed lines indicate the 95% and 99.8% control limits. 
8.5.2. Figure 14: Risk Adjusted Rate of Emergency Admission by NHS 
Trust* 
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After risk adjustment, the Trust with the highest proportion of emergency admissions admitted 
37.5% of patients as an emergency; this was not the same Trust as had the highest rate of 
emergency admissions within the crude data. The Trust with the lowest rate of admissions 
admitted 22.2% patients as an emergency; again this was not the same Trust as had the 
lowest percentage of emergency admissions within the crude data.  There did not appear to 
be a relationship between the volume of work undertaken by an individual hospital Trust and 
its rate of emergency admissions.  
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8.6. Risk of Admission as an Emergency 
Odds ratios (both unadjusted and adjusted) for emergency admission reflected the patterns 
seen in the crude data (see table 3). Overall, likelihood of emergency admission decreased 
with time (OR 0.95 (95% CI 0.95-0.96)) over the study period, whilst disease at a site other 
than within the colon was associated with a significantly decreased chance of emergency 
admission (rectosigmoid OR: 0.53 (95% CI 0.52-0.55), rectum OR: 0.31 (95% CI 0.30-0.31)). 
Sex and socioeconomic background were associated with comparatively small rises in 
likelihood of emergency admission (women OR 1.21 (95% CI 1.19-1.23), IMD Income 
Category 5 OR 1.43 (95% CI 1.39-1.47)). Advancing stage of disease was associated with 
increasing likelihood of emergency admission, with a marked increase for those with Dukes’ D 
disease (OR 11.06 (95% CI 10.53-11.62)).  
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8.6.1. Table 4: Risk of Admission as an Emergency 
Odds Ratio for Risk of Admission as an Emergency 
Unadjusted Adjusted  
  OR p 95% CI OR p 95% CI 
Sex 
 
Male 1    1    
Female 1.36 <0.01 1.34 1.38 1.21 <0.01 1.19 1.23 
Age 
≤60 1    1    
61-70 0.88 <0.01 0.86 0.90 0.84 <0.01 0.82 0.86 
71-80 1.20 <0.01 1.18 1.23 1.03 0.01 1.01 1.06 
>80 2.29 <0.01 2.24 2.35 1.80 <0.01 1.76 1.85 
Site 
Colon 1    1    
Rectosigmoid 0.53 <0.01 0.51 0.54 0.53 <0.01 0.52 0.55 
Rectum 0.30 <0.01 0.29 0.30 0.31 <0.01 0.30 0.31 
Dukes’ Stage 
A 1    1    
B 4.87 <0.01 4.65 5.11 3.74 <0.01 3.56 3.92 
C 5.81 <0.01 5.54 6.09 5.02 <0.01 4.78 5.27 
D 12.34 <0.01 11.76 12.95 11.05 <0.01 10.52 11.61 
Unknown 9.72 <0.01 9.28 10.19 8.01 <0.01 7.63 8.40 
Charlson Co-
Morbidity 
Score 
0 1    1    
1 1.90 <0.01 1.86 1.94 1.67 <0.01 1.64 1.71 
2 1.32 <0.01 1.28 1.35 1.93 <0.01 1.86 1.99 
≥3 2.31 <0.01 2.24 2.39 2.51 <0.01 2.41 2.61 
IMD Income 
Category 
Most Affluent (1) 1    1    
2 1.09 <0.01 1.06 1.11 1.06 <0.01 1.03 1.08 
3 1.20 <0.01 1.17 1.22 1.13 <0.01 1.10 1.16 
4 1.31 <0.01 1.28 1.34 1.23 <0.01 1.20 1.26 
Least Affluent (5) 1.52 <0.01 1.48 1.56 1.43 <0.01 1.39 1.47 
Year of 
diagnosis 
1998 1    0.95 <0.01 0.95 0.96 
1999 0.98 0.42 0.95 1.02     
2000 0.98 0.30 0.94 1.02     
2001 1.02 0.40 0.98 1.06     
2002 1.01 0.55 0.97 1.05     
2003 0.94 0.00 0.90 0.97     
2004 0.96 0.03 0.92 0.99     
2005 0.89 <0.01 0.86 0.92     
2006 0.81 <0.01 0.78 0.84     
2007 0.76 <0.01 0.73 0.79     
2008 0.75 <0.01 0.73 0.78     
2009 0.74 <0.01 0.71 0.76     
2010 0.70 <0.01 0.67 0.72     
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8.7. Discussion 
Over the course of the study period, the number of admissions for colorectal cancer rose 
almost every year, whilst the proportion of those admitted as an emergency fell (from 32.6% in 
1998 to 25.3% in 2010). These data show that colorectal cancer in England overwhelmingly 
remains a disease of the elderly, with women, those with greater numbers of co-morbidities 
and those from a more socioeconomically deprived background are more likely to present as 
an emergency and are also more likely to have advanced disease87,88,136,141,142. These risks 
remain even after adjustment for case mix. 
 
Those who are very young (i.e. <20 years), are also much more likely to be admitted as an 
emergency, as demonstrated by Figure 1, rather than electively. This is understandable to a 
certain degree, in that colorectal cancer is a rare condition in this age group outside of certain 
genetic syndromes. As such, unless a patient has a family history of colorectal cancer, a 
general practitioner is highly unlikely to consider colorectal cancer in a patient in this age 
group. Younger patients (i.e. <50 years) however, by nature of their age (and presumed good 
quality of life with little co-morbidity) have the most to gain from early diagnosis of colorectal 
malignancy. There is now increasing evidence of a rising incidence of colorectal cancer 
amongst ‘younger’ patients (<50 years), with a recent review of the SEER data by Bailey et al. 
noting rising incidence in those aged 20-49 years of age) and a declining incidence in older 
age groups. Bailey et al. predict that if current trends continue, a rise in the incidence of colon 
cancer of 90% and rectal cancer of 124% will be seen in the age group 20-34 years by 2030, 
with rises of 27.7% (colon) and 46% (rectal) in those aged 35-49143. If these trends are 
repeated in the European (and therefore English) population, then strategies for the 
prevention and early detection of colorectal cancer in younger patients will need to be 
developed.  
 
Early detection of colorectal malignancy through screening has a clear beneficial effect on 
likelihood of emergency admission and stage at diagnosis (Table 5.4.1), with very few 
emergency admissions and a higher percentage of Dukes’ A tumours being identified in those 
who participated in the screening program, compared with those who declined. Several 
authors (Goodyear, Scholefield, Mayor) have reported decreased rates of emergency 
admission with bowel cancer screening with others (Libby et al.) also reporting a decreased 
length of stay and reduced short-term mortality in screen-detected patients126,127,144,145. 
Further, Libby et al. note that whilst participation in screening is negatively associated with 
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socioeconomic deprivation, the effect on rates of emergency admission are independent of 
deprivation144.  
 
The studies of Libby, Goodyear, Scholefield and Mayor however have tended to report the 
results from patient populations who have been invited to participate in a screening program 
(and may therefore be more motivated that the general populace to participate).  Whilst 
screening undoubtedly brings positive results to those who participate, with cancer being 
diagnosed at an earlier, more treatable stage, the introduction of the NHSBCSP does not 
appear, when compared against population level data, to have dramatically influenced the rate 
of emergency admissions. There may well be a lag effect, and it may well be that we are only 
just beginning to see the positive impact of screening, but currently levels of participation in 
screening are only around 50% of those invited146. The most recent ‘Routes to Diagnosis’ 
work, available through the NCIN website, suggests that screen detected colorectal cancer 
diagnoses have increased from a negligible number in 2006 to ~10% of diagnoses in 2015147. 
The same work also notes that there has been a marked increase in diagnoses through 
Accident and Emergency departments (with a matching decrease through emergency GP 
admission) and may represent changing access to medical services by the general public147. 
Efforts must continue therefore, to increase the rate of take up of the NHSBCSP amongst the 
population at large, and amongst the socioeconomically deprived especially, to bring about its 
presumed beneficial effects.  
 
The volume of work undertaken by an NHS Trust did not appear to relate to the number of 
emergency admissions for colorectal cancer a hospital Trust received. Understanding the 
pattern of emergency admissions is important when trying to improve outcomes in order that 
resources may be most effectively allocated. There is evidence that the volume of work 
undertaken by a surgeon and a hospital is associated with improved outcomes148–150. Indeed, 
a key facet of improvements in Danish colorectal cancer outcomes has been the centralisation 
of colorectal services151,152. That volume of work does not appear to relate to the number of 
emergency admissions in England implies that efforts to improve English colorectal cancer 
outcomes will need to be applied throughout the health service, rather than being targeted at a 
few high volume centres to realise the greatest benefits..  
 
Socioeconomic deprivation and increasing co-morbidity have been shown here to have a clear 
deleterious impact on likelihood of emergency admission. It remains unclear as to why 
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socioeconomic deprivation may have this effect, particularly as socioeconomic deprivation has 
been shown not to deter health-seeking behaviour153. This may suggest that inequalities in 
healthcare provision in relation to colorectal cancer exist, preventing the most deprived from 
accessing care in a timely fashion. Increasing numbers of co-morbidities were demonstrated 
by Wallace et al. to increase the likelihood of emergency admission and are replicated here. In 
Wallace’s study, they argue that lack of awareness of cancer related symptoms and health-
seeking behaviour may underlie the particularly high rates seen in those with dementia87. It 
may also be possible that cancer related symptoms (loss of weight, decrease in appetite) are 
attributed too often in primary care to other conditions, or that minor changes in bowel habit or 
rectal bleeding are ignored whilst other, more immediate concerns are addressed.  
 
Strategies to reduce rates of emergency admission for colorectal cancer will likely require a 
multi-faceted approach. Key will be the identification of those most at risk in primary care, with 
particular attention paid to the potential rising incidence of colorectal cancer in younger 
patients and to the elderly who may have other conditions that mask the presence of 
colorectal cancer. Socioeconomic deprivation should not be a barrier to accessing healthcare 
in the United Kingdom and this area requires further research to determine where the barriers 
lie. Screening almost certainly has an important role to play in reducing emergency 
admissions, but efforts to increase participation and the awareness of colorectal cancer 
symptoms must continue.  
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9. Short Term Outcomes of English Colorectal Cancer 
Treatment 
 
9.1. Introduction 
Surgical resection of the tumour, with clear excision margins, remains the main treatment 
modality for early colorectal cancer, and maintains an important role in more advanced 
disease. Longer survival in colorectal cancer is due either to earlier diagnosis, better treatment 
or a combination of the two. A high resolution study using the EUROCARE-II data (Gatta et 
al.) demonstrated wide variation in five year survival rates for colorectal cancer throughout 
Europe with rates of >45% in Sweden, Switzerland, France, Italy, Spain and the Netherlands, 
compared to <35% in Slovenia and Poland54. England was intermediate at 41%. This variation 
in survival however, was confined to the first 6 months after diagnosis, after which survival 
was much more homogeneous. The wide variation in survival was also mirrored by wide 
variation in the percentage of patients who underwent surgical resection of their tumour (>85% 
in Switzerland, the Netherlands and France, <60% in Poland and Estonia). The authors of the 
EUROCARE-II study concluded that much of the survival differences between countries were 
likely due to the proportion of advanced cases at diagnosis, but given the wide variation in 
rates of surgical resection, it is also probable that rates of surgical intervention (and 
subsequent short term mortality rates) may also have made a significant contribution54.    
 
Gatta et al.’s study used outcomes for the treatment of those diagnosed and treated for 
colorectal cancer in Europe between 1985 and 1989. Analyses of the treatment of more recent 
patients have confirmed however that the previously seen variation in European outcomes 
persists, with England once again achieving poor results for survival56,57. A large audit of two 
thirds of all cases of colorectal cancer treated in England between 2007 and 2008 also 
showed that whilst 75% of patients in England underwent some form of surgical intervention, 
only 60% underwent a major resection. Further, large variation existed in the proportion of 
patients undergoing major resection by cancer network, suggesting that either there was 
variability in the patients suitable for major surgical resection, or that patients were being 
classified as unsuitable for surgery for other reasons154.   
 
Variation in short term survival following major colorectal cancer resection in England was the 
subject of a large study by Morris et al. who use the NCDR to review the 30-day mortality of 
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160,920 individuals treated within the English NHS between 1998 and 2006. Whilst overall 
mortality fell over the study period, significant variation was seen in mortality rates between 
NHS hospital Trusts, even after adjustment for case-mix63.  
 
Thus, it would appear that England has a comparably low rate of surgical resection, with wide 
variation in short-term outcomes dependent upon hospital Trust. Institutional comparison is 
difficult, with data that is not risk-adjusted presenting obvious difficulties. The NCDR is a 
useful dataset for institutional comparison being a population level dataset of routinely 
collected data. As such, it is not subject to the biases that may occur with datasets that are 
contributed to voluntarily. The data stored within the NCDR is also of good quality and 
reasonable completeness, allowing for trends in outcome to be seen. This section aims to 
build on the work of Morris et al. to assess patient characteristics associated with poor short 
term outcomes and to present risk-adjusted funnel plots to display variation in institutional 
performance.  
 
9.2. Methodology and Statistical Modelling 
Patients diagnosed with colorectal cancer between 1st January 1998 and 31st December 2010 
were identified from the NCDR database. Each patient was assessed for whether they 
underwent a major surgical resection, minor surgical resection (e.g. endomucosal resection), 
bypass, stoma formation, stent or no surgical intervention. 30 and 90-day mortality rates were 
then calculated for each group of patients depending upon their intervention, with the 
exception of those who did not undergo any form of surgical intervention, for whom no 
mortality information was available. Each group of patients was assessed for their short-term 
(30 and 90-day) mortality depending upon their index admission status (elective or 
emergency), age (at diagnosis), year of diagnosis, site of disease, Dukes’ stage, Charlson co-
morbidity score and level of socioeconomic deprivation (IMD income category). 
 
For those who underwent major surgical resection, unadjusted and adjusted odds ratios for 
likelihood of early mortality by admission status were calculated for each variable. Again, two 
hospitals Trusts were excluded from both the univariate and logistic regression analyses due 
to their provision of supra-specialist services. Statistical analyses were undertaken in StataTM 
Version 13.1 as before, with institutional comparison again being performed using the 
funnelcompar command to compare institutional short-term mortality rates with volume of 
admissions. Statistical significance was set at p≤0.05. 
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9.3. Results 
9.3.1.  Crude Mortality Figures 
275,325 patients were identified who underwent major resection, minor resection, bypass, 
stoma formation or stent insertion. 78, 567 (28.5%) patients did not undergo any form of 
surgical intervention (and were excluded). Overall mortality for all patients (whether they 
underwent resection or not) was 6.9% at 30-days and 10.9% at 90-days. Mortality by mode of 
admission and resection status is displayed in Table 5. 
 
9.3.1.1. Table 5: 30 and 90-day Mortality by Mode of Admission 
and Resection Status 
Resection Status 
30-Day Mortality 90-Day Mortality 
 All Patients All Patients 
 Alive Dead Total Alive Dead Total 
 n % n %  n % n %  
No Major 
Resection 
28187 88.4 3713 11.6 31900 24164 75.7 7736 24.3 31900 
Major Resection 228109 93.7 15316 6.3 243425 221144 90.8 22281 9.2 243425 
           
 Elective Admission Elective Admission 
 Alive Dead  Alive Dead  
 n % n %  n % n %  
No Major 
Resection 
20362 94.9 1103 5.1 21465 18498 86.2 2967 13.8 21465 
Major Resection 179211 96.4 6732 3.6 185943 175575 94.4 10368 5.6 185943 
           
 Emergency Admission Emergency Admission 
 Alive Dead  Alive Dead  
 n % n %  n % n %  
No Major 
Resection 
7825 75 2610 25 10435 5666 54.3 4769 45.7 10435 
Major Resection 48898 85.1 8584 14.9 57482 45569 79.3 11913 20.7 57482 
 
Mortality in those who underwent minor resection of their tumour at 30-days was 3.1% for all 
patients, 1.6% in those admitted electively and 14.1% in those admitted as an emergency. 30-
day mortality for all those who underwent bypass was 27.8%, stoma formation 18.7% and 
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stent insertion 18.3%. 90-day mortality was 8.4% for minor resection, 55.0% for bypass, 
37.0% for stoma formation and 37.6% for stent insertion. Mortality for those undergoing minor 
resection only was 1.6% when admitted electively at 30-days compared to 14.1% when 
admitted as an emergency. A similar trend was seen for all other procedures. 
9.3.1.2. Figure 15: 30 and 90 days Mortality in those not 
undergoing major resection 
 
30-day mortality for all patients who underwent a procedure fell from 8.1% in 1998 to 4.5% in 
2010 (90-day mortality: 12.5% 1998, 7.7% 2010) and for those who underwent a major 
resection from 7.5% in 1998 to 3.9% in 2010 (90-day mortality: 11.0% 1998, 5.9% 2010). 
 
Mortality by patient characteristic showed significantly increased mortality in men at 30 and 90 
days in the elective setting (Chi2 p<0.0001) and initially in the emergency setting (Chi2 
p<0.001) but this was lost by 90 days (Chi2 p=0.65). There was no difference in mortality by 
site of disease in the elective setting Chi2 p=10.9) but in the emergency setting, those with 
rectal cancer did significantly worse (Chi2 p<0.0001) (Table 6). 
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9.3.1.3. Table 6: Mortality by Patient Characteristic and Admission 
Status 
Mortality by  Patient Characteristic and Admission Status 
  Elective  Emergency  
  
30-Day 
Mortality 
90-Day 
Mortality 
30-Day 
Mortality 
90-Day 
Mortality 
    % % % % 
Sex 
Male 4.1 6.2 14.9 20.6 
Female 2.9 4.7 13.4 20.8 
Age 
≤60 0.9 1.8 4.2 7.7 
61-70 2.0 3.5 9.8 14.7 
71-80 4.6 6.8 16.2 22.5 
>80 8.3 11.9 26.1 33.8 
Site 
Colon 3.7 5.8 14.6 20.4 
Rectosigmoid 3.3 5.3 15.9 21.5 
Rectum 3.5 5.3 18.4 24.6 
Dukes’ 
Stage 
A 2.8 3.9 10.5 13.8 
B 3.4 4.8 13.1 16.5 
C  3.4 5.4 13.5 19.0 
D 4.1 9.5 14.6 26.1 
Unknown 5.5 7.9 26.1 33.2 
Charlson 
Co-
Morbidity 
Score 
0 2.9 4.6 11.2 16.5 
1 5.9 8.3 20.2 26.7 
2 7.6 11.0 26.8 34.7 
≥3 12.5 17.3 37.7 45.3 
IMD 
Income 
Category 
Most Affluent (1)  3.0 4.8 12.9 18.9 
2 3.4 5.2 13.7 19.2 
3 3.7 5.6 15.3 21.1 
4 3.9 6.0 16.2 21.9 
Least Affluent (5) 4.3 6.6 16.4 22.4 
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9.4. Risk of Death at 30 and 90 days 
Odds ratios for risk of death at both 30 and 90 days were similar to the results of the crude 
data. Women were less likely to die in the elective setting at both 30 and 90 days but there 
was no difference in risk of death by sex if admitted as an emergency (Tables 7 and 8).  
9.4.1. Table 7: Risk of Mortality at 30 days by Admission Status 
Adjusted Odds Ratios for Mortality at 30 days  
    Elective Admission Emergency Admission 
    OR p 95% CI OR p 95% CI 
Sex 
Male 1    1    
Female 0.65 <0.01 0.62 0.69 0.97 0.20 0.92 1.02 
Age 
≤60 1    1    
61-70 2.22 <0.01 1.96 2.52 2.38 <0.01 2.12 2.66 
71-80 5.14 <0.01 4.57 5.78 3.99 <0.01 3.59 4.42 
>80 10.50 <0.01 9.31 11.83 7.49 <0.01 6.75 8.31 
Site 
Colon 1    1    
Rectosigmoid 0.99 0.91 0.91 1.09 1.12 0.034 1.01 1.25 
Rectum 1.13 <0.01 1.07 1.19 1.29 <0.01 1.17 1.42 
Dukes’ Stage 
A 1    1    
B 1.08 0.072 0.99 1.18 1.36 0.001 1.14 1.63 
C 1.23 <0.01 1.13 1.34 1.56 <0.01 1.31 1.87 
D 1.76 <0.01 1.57 1.98 2.13 <0.01 1.77 2.56 
Unknown 1.96 <0.01 1.78 2.16 3.66 <0.01 3.04 4.40 
Charlson Co-
Morbidity 
Score 
0 1    1    
1 1.87 <0.01 1.75 1.99 1.80 <0.01 1.70 1.91 
2 2.39 <0.01 2.18 2.63 2.49 <0.01 2.29 2.70 
≥3 3.97 <0.01 3.57 4.43 4.25 <0.01 3.86 4.68 
IMD Income 
Category 
Most Affluent (1) 1    1    
2 1.11 0.009 1.03 1.21 1.03 0.521 0.95 1.12 
3 1.15 0.001 1.06 1.25 1.14 0.001 1.05 1.24 
4 1.21 <0.01 1.12 1.32 1.22 <0.01 1.13 1.32 
Least Affluent (5) 1.34 <0.01 1.23 1.46 1.30 <0.01 1.19 1.41 
Year of diagnosis 0.95 <0.01 0.94 0.95 0.98 <0.01 0.97 0.98 
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9.4.2. Table 8: Risk of Mortality at 90 days by Admission Status 
Adjusted Odds Ratios for Mortality at 90 days  
  Elective Admission Emergency Admission 
   OR p 95% CI OR p 95% CI 
Sex 
Male 1    1    
Female 0.70 <0.01 0.67 0.73 0.97 0.164 0.93 1.01 
Age 
≤60 1    1    
61-70 1.95 <0.01 1.79 2.14 2.03 <0.01 1.86 2.22 
71-80 3.93 <0.01 3.61 4.27 3.34 <0.01 3.08 3.63 
>80 7.95 <0.01 7.28 8.67 6.25 <0.01 5.75 6.78 
Site 
Colon 1    1    
Rectosigmoid 1.00 0.91 0.93 1.08 1.07 0.186 0.97 1.17 
Rectum 1.11 <0.01 1.06 1.16 1.25 <0.01 1.15 1.36 
Dukes’ Stage 
A 1    1    
B 1.12 0.003 1.04 1.20 1.31 0.001 1.12 1.54 
C 1.43 <0.01 1.33 1.54 1.73 <0.01 1.48 2.03 
D 3.12 <0.01 2.86 3.41 3.35 <0.01 2.85 3.95 
Unknown 2.08 <0.01 1.92 2.26 3.79 <0.01 3.21 4.47 
Charlson Co-
Morbidity 
Score 
0 1    1    
1 1.70 <0.01 1.61 1.79 1.70 <0.01 1.61 1.79 
2 2.28 <0.01 2.11 2.47 2.40 <0.01 2.22 2.59 
≥3 3.75 <0.01 3.41 4.12 3.89 <0.01 3.55 4.27 
IMD Income 
Category 
Most Affluent (1) 1    1    
2 1.06 0.083 0.99 1.13 0.98 0.554 0.91 1.05 
3 1.12 0.001 1.05 1.19 1.09 0.022 1.01 1.17 
4 1.18 <0.01 1.10 1.26 1.14 <0.01 1.06 1.23 
Least Affluent (5) 1.31 <0.01 1.22 1.41 1.22 <0.01 1.13 1.32 
Year of diagnosis 0.94 <0.01 0.94 0.95 0.97 <0.01 0.97 0.98 
 
The elderly, those with advanced disease, those with greater co-morbidity and those from a 
socioeconomically deprived background were all more likely to die at both 30 and 90 days. 
Patients with rectal cancer had a higher risk of mortality in both the elective and emergency 
settings at both 30 and 90 days. Those with cancer of the rectosigmoid junction had a slightly 
higher risk of death in the emergency setting at 30 days (OR 1.12, p= 0.034, 95%CI 1.01-1.25) 
compared to those with colon cancer, but otherwise, there was no difference in risk of short-
term mortality between those with colon cancer and cancer of the rectosigmoid junction.  
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9.5. Mortality by Hospital Trust 
Crude rates of mortality by hospital Trust ranged from 1.4- 7.2% in the elective setting at 30 
days (median 3.6%) to 6.7- 28.5% in the emergency setting (median 15.1%), again at 30 
days. 90 days mortality rates ranged from 2.9- 9.6% (elective, median 5.6%) and 10.2- 35.2% 
(emergency, median 20.9%).  
9.5.1. Table 9: Highest and Lowest Crude Rates of Mortality by Hospital 
Trust 
Crude Mortality Figures by Hospital Trust 
  30 Day Mortality 
 Trust Elective Admission Emergency Admission 
  Alive   Dead  Total Alive   Dead  Total 
  n % n %  n % n %  
 Lowest 
Mortality 
783 98.6 11 1.4 794 194 93.3 14 6.7 208 
 Highest 
Mortality 
415 92.8 32 7.2 447 191 71.5 76 28.5 267 
            
  90 Day Mortality 
 Trust Elective Admission Emergency Admission 
  Alive   Dead  Total Alive   Dead  Total 
  n % n %  n % n %  
 Lowest 
Mortality 
705 97.1 21 2.9 726 141 89.8 16 10.2 157 
 Highest 
Mortality 
320 90.4 34 9.6 354 173 64.8 94 35.2 267 
 
A total of 22 Trusts were above the 95% control limit for mortality at 30 days and 25 at 90 days 
for those admitted electively (Table 10, Figures 16 and 18), compared with 18 Trusts above 
the 95% control limit at 30 days and 17 at 90 days for emergency admissions. Trusts below 
the 95% control limit for both 30 and 90 days are set out in Table 11. Frequently, Trusts either 
above or below the 95% control limit at 30 days were also above or below the limit at 90 days.  
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9.5.2. Table 10: Numbers of Trusts above or below 95% and 99.8% 
Control Limits 
Numbers of Trusts above or below Control Limits 
Mortality 
Above Control Limit Below Control Limit 
Elective Admission Emergency Admission Elective Admission Emergency Admission 
95% 99.8% 95% 99.8% 95% 99.8% 95% 99.8% 
30 Days 13 9 15 3 16 4 15 4 
90 Days 17 8 11 6 14 4 8 5 
 
 
9.5.3. Table 11: Numbers of Trusts above or below 95% Control Limits 
at both 30 and 90 days 
Numbers of Trusts above or below Control Limits at both 30 and 90 days 
Control Limit 
Elective Admission Emergency Admission 
95% 99.8% 95% 99.8% 
Above 6 6 5 1 
Below 8 3 4 4 
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9.5.4. Figures 16 and 17: 30-Day Risk Adjusted Mortality by Hospital 
Trust and Admission Method* 
 
 
*Red lines indicate overall mortality rate; dashed lines indicate the 95% and 99.8% control limits 
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9.5.5. Figures 18 and 19: 90 Day Risk Adjusted Mortality by Hospital 
Trust and Admission Method* 
 
 
*Red lines indicate mortality admission rate; dashed lines indicate the 95% and 99.8% control limits 
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Figures 14-17 would appear to show one Trust whose mortality rate was markedly higher for 
both elective and emergency admissions at 30 and 90 days. This was the same Trust in 
relation to emergency admissions, but different Trusts for elective admissions.  
 
9.6. Discussion 
The overall mortality rate recorded for the duration of the study period of 6.9% at 30 days is 
broadly in line with other authors63,129. The fall in overall mortality from 7.5% in 1998 to 3.9% in 
2010, may suggest that recent efforts to reduce mortality from colorectal cancer are beginning 
to have an impact. What must be borne in mind however, is that although rates for the 
treatment of colorectal cancer in England have improved over the study period, so have the 
rates in other countries. As such, the disparity in English colorectal cancer outcomes remains, 
albeit at a lower level of mortality (e.g. EUROCARE V, 5-year survival from colon cancer, 
European average 57.0%, England 51.8%). It would appear that England still has a 
comparatively low rate of patients undergoing major resection (68.8% of all patients) 
compared with other parts of Europe, although this may be an unfair comparison once those 
who are unfit for any form of surgical intervention are removed; over 88% of those suitable for 
intervention received a major resection. 
 
The high mortality rates seen in those who did not undergo major resection are unsurprising 
(with the exception of  the very low mortality rates in those undergoing elective minor 
resection, who are likely to have had early stage disease, suitable for endoscopic removal or, 
in recent years innovations such as trans-anal endoscopic microsurgery). What is striking from 
these data is that those who undergo a bypass procedure seem to fair much worse than those 
undergoing stoma formation or stent insertion. However these patients are likely to have been 
those with advanced disease, in which bypass was a procedure of last resort; hence it is 
unsurprising they had such poor results. 
 
The observations that absolute numbers of deaths and risk of death are highest in the elderly, 
those with advanced disease and greater co-morbidity is not new, nor is the clear 
demonstration from these data that emergency presentation is a negative predictor of 
outcome in almost every case. The persistence of the large disparities in outcome between 
these groups however suggests that there has only been limited success in improving 
outcomes for this group of vulnerable patients. Given that it is well recognised that England 
has a high proportion of elderly patients, with high numbers of co-morbidities presenting as 
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emergencies, earlier identification of these patients, with clear strategies for their 
management, should they present in an unplanned manner, would seem a priority.  
 
The rising risk of short-term mortality associated with increased socioeconomic deprivation 
would suggest that there is inequality of access to treatment throughout England. The 
previous finding within this study and in many others, that socioeconomic deprivation is a risk 
factor for emergency presentation reinforces this argument88,132,133,155.  
 
The large amount of variability in outcomes between hospital Trusts reinforces the findings of 
the studies by Morris et al and Warwick et al63,101. Whilst these figures are not suitable for 
direct institutional comparison, as no effort has been made to account for missing data and the 
impact this may have on an individual Trust’s performance, these figures demonstrate how 
outcomes vary across England. Local factors, such as the population a Trust serves will 
certainly have played a part in the variability of outcomes but this does not adequately explain 
such broad differences (particularly as those Trusts who performed poorly electively, also 
tended to perform poorly in the emergency setting). It is likely that high performing Trusts have 
policies and procedures in place for the management of both elective and emergency 
colorectal cancer patients where dissemination would be of benefit to many other Trusts. 
 
Examples of such policies or procedures however tend to be restricted to the local level 
however. Whilst there are national guidelines for the management of the colorectal cancer 
patient (e.g. NICE/ ACPGBI), there appears to be an opportunity for successful local 
management strategies to be brought together for others to view before adapting them to local 
needs. The English NHS expends much effort trying to ensure consistency of quality and 
outcomes through organisations such as NHS Improvement or the Care Quality Commission 
but a forum for the easy dissemination of innovative practice is lacking.  
 
Short-term mortality from colorectal cancer appears to be falling throughout England, but it 
does not appear to be falling at a rate faster than our European neighbours and therefore 
disparities in outcomes remain. There appears to be persistent wide variation in outcomes, 
both in the elective and emergency settings and an opportunity for the dissemination of good 
practice exists.  Discrepancy in outcomes will always exist for a multitude of reasons, but until 
a greater degree of consistency of outcome exists between hospital Trusts, particularly for 
94 
 
 
those at highest risk, then English colorectal cancer outcomes will fail to improve. Efforts 
should therefore be focused on earlier diagnosis, especially amongst the elderly and the 
socioeconomically deprived, with measures put in place to pass on successful management 
strategies. It is likely that, as large, contemporary databases such as NBOCAP gather more 
information, this will become progressively easier to achieve.  
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10. The Changing Face of English Colorectal Cancer 1998-
2010 
10.1. Introduction 
Colorectal cancer in high incidence countries (e.g. Australia, Denmark, Norway), has 
remained at a steady incidence since a peak in the mid-1980s, but continues to rise rapidly in 
some traditionally low risk areas such as Japan, Korea and China45,156,157.  The incidence of 
CRC in England has recently begun to slowly rise again, in part as a consequence of the 
ageing English population but also due to a rise in age-specific incidence, especially among 
men aged between 65 and 84. This rise in age-specific incidence is accompanied by marked 
variation in regional incidence rates across England, suggesting that lifestyle and 
environmental factors may also be contributing to this variation158.  
 
Nevertheless, over the time period covered by this study, alongside changes in colorectal 
cancer incidence in England, there were notable changes in approach to the management of 
cancer throughout the United Kingdom and a variety of innovative treatment options 
specifically for those with colorectal cancer. 1998-2010 covers the period where poor English 
cancer outcomes were truly recognised and efforts made to improve these (Calman-Hine 
Report, NHS Cancer Plan, Improving Outcomes: A Cancer Strategy). The introduction of the 
NHS Bowel Cancer Screening Program (NHSBCSP) occurred and keyhole (laparoscopic 
surgery) was introduced, as were endoluminal stents (although these will be discussed in a 
later section).  
 
Thus, the routes that colorectal cancer patients took to achieve admission for their disease will 
have changed over the study period, patients will have increasingly been treated by colorectal 
specialists, rather than by generalists with specialist support and laparoscopic surgery will 
have impacted on patient’s lengths of stay. 
 
This chapter therefore aims to demonstrate how, through use of population level data, 
colorectal cancer admissions changed between 1998-2010, how mortality changed and the 
impact that innovations such as laparoscopic surgery and the NHSBCSP had on that mortality 
and how the on-going drive to improve the quality of colorectal services offered to patients 
impacted on lengths of stay.   
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10.2. Methodology and Statistical Modelling 
Data on all individuals aged 14 and over diagnosed with colorectal cancer (ICD10 C18-20) 
was extracted from the NCDR for the period January 1st 1998 to December 31st 2010. 
Information on age, sex, patient management and date of death was retrieved. Trends over 
time were compared by dividing the population into four time periods (1998-2001, 2002-
20044, 2005-2007, 2008-10) dependent upon time at. Mode of admission for each individual 
was noted (elective/ emergency) along with site of disease, Dukes’ stage, Charlson co-
morbidity score and level of socioeconomic deprivation (IMD income category). Length of stay 
was recorded, type of procedure (laparoscopic or open) and 30-day and 90-day mortality 
noted. Where appropriate, logistic regression was used to calculate risk of death, with 
adjustment being made for sex, age, stage of disease, Charlson co-morbidity score and IMD 
Income Category. Statistical differences were evaluated using Chi2. Again all analyses were 
conducted using Stata Version 13.1 with statistical significance set at p<0.05.  
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10.3. Results 
10.3.1. Admission Status 
Over the study period, 353 892 patients were admitted with colorectal cancer, of which 
emergencies made up 32.6% of admissions in 1998. There was a steady, almost year-on-year 
rise in the number of admissions for CRC from 23,999 in 1999 to 31,085 in 2010. By 2010, the 
percentage of emergency admissions had decreased to 25.3% (Figure 20). When subdivided 
by site of disease, colon cancer patients persistently had the greatest proportion of emergency 
admissions in each time period, followed by those with rectosigmoid cancer, then rectal 
cancer. 
10.3.1.1. Figure 20: Mode of Admission by Year of Diagnosis 
 
 
Those aged >80 comprised the greatest proportion of emergency admissions, however this 
age group also saw the greatest drop in emergency admissions as a percentage of total 
admissions in this age category over the study period (Figure 21) 
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10.3.1.2. Figure 21: Percentage of Emergency Admissions by Age 
Category 
 
 
The year 2006 saw the introduction of the NHS Bowel Cancer Screening Program using 
faecal occult blood testing (FOBT). Those who engaged with the screening program had a 
markedly better rate of elective admission compared with those who did not (Figure 22). This 
rate of elective admission continued to be better (compared with those who had not engaged 
in screening) when those who had engaged but were diagnosed with their cancer in-between 
tests (i.e. an interval diagnosis) were removed. Those with an interval diagnosis had an 
elective/ emergency admission rate much closer to those who did not engage in the program 
at all (Screen diagnosis 98.0% elective admission, 2.0% emergency admission; Interval 
diagnosis 79.2% elective admission, 20.8% emergency admission). Those who engaged with 
the screening program also had a much higher rate of early stage disease than those who 
chose not to participate (Figure 23). 
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10.3.1.4. Figure 22: Admission Status by Screening Method 
 
10.3.1.5. Figure 23: Screening Status by Stage of Disease 
 
Despite the improvements in emergency admission rates over the study period, the actual 
percentage of patients who underwent major resection of their cancer decreased over the 
study period from 72.8% (1998-2001) to 66.6% (2008-2010) (Chi2 p<0.001). The percentage 
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of those who underwent no surgical procedure rose from 19.4% (1998-2001) to 22.6% (2008-
2010) (Chi2 p<0.001). 
 
10.3.2. Mortality at 30 and 90 days 
Mortality for all patients undergoing surgical intervention (major resection, minor resection, 
bypass, stoma or stent) between 1998 and 2010 at 30-days was 6.9% and at 90-days 10.9%. 
30-day mortality within the time periods fell from 8.0% (1998-2001) to 5.2% (2008-2010) and 
90-day mortality from 12.5% (1998-2001) to 8.5% (2008-2010) (Chi2 p<0.001). 
 
Mortality at 30-days was greatest in those who underwent major resection for colon cancer 
and least in those undergoing resection for rectal cancer, this pattern remaining constant 
throughout the study period. The pattern was replicated in mortality at 90-days (see Figures 
24 and 25). 
10.3.2.1. Figure 24: 30-Day Mortality by Period of Diagnosis and 
Site of Disease  
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10.3.2.2. Figure 25: 90-Day Mortality by Period of Diagnosis and 
Site of Disease 
 
Mortality at 30-days rose consistently as age at diagnosis increased, as illustrated by Figure 
26 (the same pattern was replicated at 90-days). 
10.3.2.3. Figure 26: 30-Day Mortality by Age at Diagnosis, Time 
Period and Site of Disease 
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All patient mortality at 30-days in those who presented electively was 3.8%, whilst at 90-days, 
it was 6.4% (p<0.001 Chi2); for those who presented as an emergency it was 16.5% and 
24.6% (p<0.001 Chi2) respectively. 
Mortality for elective patients (at 30-days) decreased from 4.9% in 1998 to 2.4% in 2010 
(p<0.001 Chi2); emergency patients decreased from 16.7% to 13.0% (p<0.001 Chi2). At 90-
days, the figures were 8.1% (1998) to 4.4% (2010, elective patients, p<0.001 Chi2) and 24.2% 
(1998) to 20.6% (2010, emergency patients, p<0.001 Chi2). Stage of disease was not 
associated with a significant difference in mortality at 30-days (between Dukes’ stages A-D in 
the elective setting (p=0.38 Chi2) but was in the emergency setting (p=0.05 Chi2) (Figure 27). 
A similar pattern of mortality for stage of disease was repeated at 90-days. Factors associated 
with early mortality were the same as those identified in Chapter 4, namely increasing age, 
advanced stage of disease and greater co-morbidity. 
 
10.3.2.4. Figure 27: 30-Day Mortality by Admission Status, Time 
Period and Stage of Disease 
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10.4. Laparoscopic Surgery 
Over the duration of the study period, the introduction of laparoscopic surgery saw ‘keyhole’ 
procedures develop from a novel technology to becoming commonplace. This rapid rise in its 
use is demonstrated in Table 15, where laparoscopic procedures constituted 0.5% major 
resections in 1998-2001 to 26.4% in 2008-2010 (Table 12; note the ICD code for conversion 
to open procedure was introduced in 2005 onwards).  
10.4.1. Table 12: Number of Laparoscopic Procedures by Time Period 
Numbers of Laparoscopic Procedures by Time Period 
Approach 
Time Period 
1998-2001 2002-2004 2005-2007 2008-2010 
n % n % n % n % 
Open 71,129 99.5 52,474 98.4 51,187 89.7 42,389 68.9 
Laparoscopic 355 0.5 836 1.6 5,174 9.1 16,233 26.4 
Converted to Open 0 0.0 0 0.0 726 1.3 2,922 4.7 
Total 71,484   53,310   57,087   61,544   
 
No specific site of disease appears to have been favoured for a laparoscopic approach, with 
approximately equal rates of conversion to open procedure at each site of disease (Figure 28). 
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10.4.2. Figure 28: Percentage of Laparoscopic Procedures by Time 
Period and Site of Disease 
 
Unsurprisingly, the majority of laparoscopic procedures were in those admitted electively, but 
by 2008-2010, a small but significant percentage of procedures were either performed or were 
attempted laparoscopically in those admitted as an emergency (8.1% of all major resections, 
2008-2010). 
Mortality was significantly lower in those who underwent a laparoscopic procedure, with 
adjusted odds ratios for risk of death at 30-days following major resection in elective patients 
being 0.63 and for emergency patients 0.29 (time period 2008-2010, Table 13). No difference 
was found in risk of death if a procedure was converted to open. A similar pattern was seen 
for outcomes at 90-days.  
Given the large discrepancy in numbers of laparoscopic procedures carried out within the 
different time periods and the likelihood of a significant ‘learning effect’, comparison of length 
of stay by time period was not carried out. Suffice to say however that those who underwent a 
laparoscopic procedure consistently remained in hospital for a shorter duration than those 
undergoing an equivalent open procedure.  
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10.4.3. Table 13: Crude figures and Odds Ratios for Likelihood of 
Death at 30-days by Operative Approach (2008-2010) 
 
Crude figures and Odds Ratios for Likelihood of Death at 30-days by Operative Approach 
Elective Admission 
Operative 
Approach 
Crude Mortality Odds Ratios 
Alive  Dead Alive  Dead Unadjusted Adjusted 
n % n % OR p 95% CI OR p 95% CI 
Open  30,440 97.0 952 3.0 1    1    
Laparoscopic 15,214 98.2 280 1.8 0.59 <0.001 0.51 0.67 0.63 <0.001 0.55 0.72 
Converted 2,616 97.1 77 2.9 0.94 0.61 0.74 1.19 0.97 0.77 0.76 1.23 
Emergency Admission  
Operative 
Approach 
Crude Mortality Odds Ratios 
Alive  Dead Alive  Dead Unadjusted Adjusted 
n % n % OR p 95% CI OR p 95% CI 
Open  9507 86.5 1490 13.5 1    1    
Laparoscopic 706 95.5 33 4.5 0.3 <0.001 0.21 0.42 0.29 <0.001 0.2 0.42 
Converted 212 92.6 17 7.4 0.51 <0.001 0.31 0.84 0.61 0.06 0.36 1.02 
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10.5. Length of Stay 
Median length of stay for all patients who underwent a surgical procedure throughout the 
course of the study was 9 days (IQR 8). In those admitted electively it was also 9 days (IQR 7) 
whilst median length of stay for an emergency admission was 10 days (IQR 12). Length of 
stay by admission status and primary procedure is demonstrated in Table 14. 
 
10.5.1. Table 14: Length of Stay by Admission Status and Primary 
Procedure 
Post-Procedure Median Length of Stay 
Primary Procedure 
Median Length of Stay (Days) 
All Patients Elective Admission Emergency Admission 
Major resection 10 (8) 9 (7) 10 (11) 
Minor resection 0 (1) 0 (1) 4 (11) 
Bypass 10 (10) 10 (8) 11 (12) 
Stoma 10 (10) 9 (8) 11 (13) 
Stent 2 (5) 1 (7) 3 (8) 
*Values in parentheses are the inter-quartile range.  
Median length of stay decreased for all patients undergoing a surgical procedure (see Table 
15) but most notable was the decrease in length of stay in those who underwent major 
resection. 
10.5.2. Table 15: Length of Stay by Primary Procedure and Time 
Period 
Post-Procedure Length of Stay by Time Period (All Patients) 
Primary Procedure 
Time Period 
1998-2001 2002-2004 2005-2007 2008-2010 
Major resection 11 (7) 10 (8) 9 (7) 7 (8) 
Minor resection 1 (3) 0 (2) 0 (1) 0 (0) 
Bypass 11 (9) 11 (10) 9.5 (10) 9 (10) 
Stoma 12 (10) 11 (10) 9 (10) 8 (9) 
Stent 3 (5) 2 (5) 2 (6) 1 (5) 
*Values in parentheses are the inter-quartile range.  
Comparison of length of stay by admission status, time period (of diagnosis) and site of 
disease revealed that those with colon cancer remained in hospital for the shortest period, 
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followed by those with rectosigmoid cancer, with rectal cancer patients staying the longest 
(Figure 29). 
10.5.3. Figure 29: Length of Stay by Admission Status, Time Period 
and Site of Disease 
 
Those admitted as an emergency consistently stayed longer than those admitted electively 
although this was not statistically significant (p=0.93 Chi2).   
10.6. Discussion 
This study demonstrated a consistent rise in the number of patients admitted with colorectal 
cancer (CRC) over its course, with the number of those admitted electively rising whilst the 
number of those admitted as an emergency fell. This pattern of rising incidence of CRC has 
been replicated in other nations beyond England/ the United Kingdom, including the United 
States, Asia and the Oceanic nations, with the highest rise in incidence seen in economically 
transitioning nations, particularly those of the old Eastern Bloc159–162. Further, several of these 
nations have also seen a comparative rise in the incidence of CRC amongst younger patients, 
a trend again replicated here159,161,162. Reasons underlying these changes in incidence are 
likely to include an ageing population and better and more successful treatments of other 
diseases (allowing people who previously would have died of alternative causes e.g. heart 
disease, to develop CRC). Amongst the young, changes in diet and lifestyle may well be 
contributory, especially as populations become wealthier with a concomitant rise in the 
consumption of red meat and processed foods and decrease in levels of physical activity163,164.  
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The fall in the number of elderly (>80 years) admitted as an emergency and the fall in the 
number of emergency admissions in general over the study period may suggest that despite 
its critics, innovations such as the two-week wait and the 31/62 day cancer targets may be 
having a positive impact on CRC diagnoses and the route of admission for those found to 
have CRC165–169.  
 
The dramatic effect that screening can have on emergency presentation was clearly 
demonstrated within these results and is again a picture that has been replicated within other 
countries170. Further these results provide an excellent example of how ‘Big Data’ may 
demonstrate at a population level (where perhaps at a local level it may be more difficult to 
ascertain) how interventions affect stage at diagnosis and route of admission.  For those with 
interval cancers (who had almost the same risk of emergency admission as those who had not 
engaged in the screening program), two explanations are most likely. These patients may 
have had a missed cancer, either through failure of the FOBT or unfortunate failure of the 
endoscopist to recognise a small cancer at time of investigation or they may have developed 
highly aggressive disease, where progression occurs within the screening timeframe.  
 
The trend towards steadily improving 30 and 90-day mortality for those patients who undergo 
operative intervention is suggestive of better patient selection (and in turn better non-operative 
treatments for frail patients e.g. endoluminal stents) but also recognition of the increasing 
importance that peri-operative care is having on patient outcomes. ‘Failure to rescue’ has 
been recognised as a concept, with greater emphasis being placed on timely review, 
investigation (e.g. much greater use of early post-operative imaging) and patient management 
by senior doctors. Technological advances such as radiological drainage of post-operative 
collections have now also obviated the need for repeat surgical intervention along with its 
attendant risks. Much greater importance is now placed on prevention of thromboembolic 
events, cardiac pre-habilitation and objective physiological testing of a patient’s ability to 
undergo the rigours of major surgical intervention (e.g. CPEX testing), along with greater use 
of devices such as incentive spirometers to prevent post-operative chest infections.  
 
The introduction of laparoscopic surgery represented a major development within the 
treatment of colorectal disease and a similar change in surgical technique. Whilst trials such 
as CLASICC and COLOR showed that there was no difference in oncological outcome, 
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laparoscopic surgery (like all surgical techniques) was associated with a learning curve171,172. It 
is highly likely that the positive results in terms of post-operative mortality, particularly with 
earlier results may have been influenced by very careful patient selection, but it is also 
important to note that at a population level, those undergoing a laparoscopic resection 
certainly did not do any worse than their ‘conventionally’ treated peers. Results from a cohort 
of patients undergoing laparoscopic surgery today are likely to show that they do significantly 
better than those who undergo an open operation (as laparoscopic surgery is now the 
accepted norm, with open surgery being reserved for those with disease related or patient 
factors which prevent a laparoscopic approach).  
 
The fact that by the end of the study period, a small but significant number of patients who 
were admitted as an emergency were undergoing a laparoscopic procedure, perhaps provides 
insight into the readiness with which laparoscopic surgery was accepted into the surgical 
community. Surgery has a long history of innovation but uptake of new techniques or 
innovative equipment has at times been reluctant173. The fact that within a 13-year period, 
laparoscopic surgery went from introduction to the accepted norm for elective resection with 
small but increasing numbers being performed in the emergency setting, demonstrates how 
readily the benefits of laparoscopic surgery were realised and the effort that was made by 
surgeons to ‘upskill’ themselves to be able to provide this service.   
 
With the recognised reduction in length of stay associated with laparoscopic surgery (due to 
less post-operative pain and earlier mobilisation), it is perhaps not surprising that length of 
stay fell. Nonetheless, the importance of the introduction of enhanced recovery protocols and 
the use of post-operative analgesic regimens allowing early mobilisation/ prevention of chest 
infections and encouragement of return of gut function should not be underestimated. These 
changes all occurred concurrently with the introduction of laparoscopic surgery over the 
duration of this study and the combined impact of these interventions is well demonstrated by 
the data provided here. Like with most aspects of life, it is the cumulative effect of marginal 
gains that result in the greatest impacts.   
 
Overall, therefore, it would appear that the rising incidence of colorectal cancer is being 
replicated in England as in other developed nations. Reasons underlying this are, as always, 
multifactorial but the rising incidence in younger patients is of particular concern. Patients are, 
in general, being identified earlier through increased focus on CRC and interventions such as 
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screening. Mortality rates are improving as more attention is being paid to peri-operative care 
(peri-operative care consultants are even being introduced in parts of the NHS) along with 
other improvements in care (such as laparoscopic surgery) resulting in decreased length of 
stay and reductions in preventable post-operative complications. These improvements are not 
happening in isolation in England however, they are occurring across the developed world. As 
such the English NHS in terms of colorectal cancer care is ‘running furiously to stand still’ in 
comparison to our European/ Oceanic and American partners. To surpass the standards of 
care and outcomes achieved in other wealthy nations, still greater improvements to English 
colorectal cancer care need to occur.  
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11. Endoluminal Stent Use in English Colorectal Cancer 
Patients 1998-2010 
11.1. Introduction 
In 2010 there were 40,695 new cases of colorectal cancer in the UK, with emergency 
presentation constituting a fifth (21%) of all new diagnoses. 174,175 By 80 years of age, rates of 
emergency admission increase to 40%, of whom nearly a third of patients (29.5%) are 
unsuitable for operative intervention92,175,176. Acute colonic obstruction has been reported in 
between 7-30% of all colorectal cancer presentations, particularly in those with lesions distal 
to the splenic flexure176. Traditionally, management has involved the use of one, two or even 
three stage operative procedures to relieve the obstruction and resect the tumour. Emergency 
surgery however, by its nature, is high risk and is especially so when operating on patients 
with malignant large bowel obstruction. Such patients are not optimised for surgery, often 
have associated co-morbidities and are suffering the acute physiological derangement of 
colonic obstruction177. 
 
The use of novel medical devices therefore that may achieve endoluminal decompression and 
convert the acutely obstructed patient to one who may undergo pre-operative optimisation 
prior to major resectional surgery is an understandably attractive option. Balloon dilatation and 
laser re-canalisation have historically been attempted to relieve the obstructed patient, 
however both are subject to limitations. Balloon dilatation risks perforation and tumour 
fracture, whilst laser re-canalisation is not widely available and often requires  multiple 
treatments before adequate decompression is achieved, thus limiting its use in the emergency 
setting178. The current guidelines from both The Association of Coloproctology of Great Britain 
and Ireland and NICE recommend that “in the absence of perforation, peritonitis or closed loop 
obstruction, endoluminal stent insertion should be considered in the management of malignant 
colorectal obstruction3,179.” 
 
Dohmoto first reported the use of an endoluminal stent in the management of acute colonic 
obstruction in 1991180. Under a combination of endoscopic and fluoroscopic guidance, self-
expanding stents may be inserted into the colorectum in order to allow proximal 
decompression from an obstructing lesion. Successful deployment of a stent offers almost 
immediate decompression allowing either palliation or to act as a bridge to surgery. Technical 
success rates of up to 92% and clinical success rates of up to 88% have been reported in the 
published literature181,182. 
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Whilst, there has been a steady rise in the use of endoluminal stents since their introduction, 
this rise has been based on limited randomised controlled evidence; in fact a number of 
controlled clinical trials have been stopped due to high rates of adverse events.183,184 Early 
results from the CREST trial have shown that use of endoluminal stents in the emergency 
setting have similar outcomes in terms of mortality and length of stay to that of emergency 
surgery, but result in decreased rates of stoma formation when compared to immediate 
surgery185. Nevertheless, use of endoluminal stents remains controversial and retrospective 
analysis of large population based datasets may contribute towards the evidence base for 
their use in obstructing colorectal cancer.  
 
Through use of linked Cancer Registry and HES data in the form of the National Cancer Data 
Repository (NCDR) a retrospective analysis of the patterns of use and outcomes of 
endoluminal stents in the management of acute malignant colonic obstruction between 1998 
and 2010 within the English NHS has been performed and is the subject of this chapter. This 
chapters aims to describe how the use of endoluminal stents has influenced the management 
of acute malignant colonic obstruction and how their outcomes have developed over the study 
period. 
  
11.2. Methodology and Statistical Modelling 
Data were extracted from the NCDR on all individuals with a diagnostic code indicating first 
primary diagnosis of colorectal cancer between 1998 and 2010. Individuals identified were 
limited to those with codes for insertion of any endoscopic, image-guided or self-expanding 
metal stent. These individuals were then further limited to OPCS codes (Version 4.5, 2009) 
H21.4, H24.3, H24.4, H27.3, H27.4, H31.4 for stents inserted into the colorectum and to 
stenting within one year of their diagnosis. 
 
Identified individuals were limited to a single episode of stent insertion before de-duplication. 
Data were extracted on the total number of stents placed within each year, the location of the 
placement of the stent (derived from the recorded site of the tumour, taken from the cancer 
registry component of the NCDR) and the 30-day mortality associated with stent placement 
(defined as time from date of stent insertion to date of death). Other analyses performed 
included time from admission to stent insertion (as recorded within HES), 30-day mortality in 
those undergoing operative intervention (defined as set out in the NCIN Major Surgical 
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Resections report186) and overall survival (defined as survival from date of stent insertion to 
date of death). For purposes of survival analysis, analysis began from the date of stent 
insertion and the data was censored at 5 years. 
 
Individuals were categorised as ‘Stent Only’ if a stent was their only recorded intervention or if 
a recorded colorectal operation occurred before stent insertion with no recorded surgery 
thereafter. ‘Bridge to surgery’ was defined as those who underwent an operation greater than 
48 hours after their recorded date of stent insertion. ‘Stent Fail’ was defined as those who 
underwent stent insertion but had a recorded operative intervention within 48 hours. 
 
In those undergoing surgery, OPCS codes were used to tabulate all procedures performed 
prior to grouping. ‘Restorative Resection’ was defined as any operation that involved 
segmental colonic or rectal resection and anastomosis. ‘Hartmann’s/ Stoma’ was defined as 
any OPCS code that included either formation of an ileostomy or exteriorisation of bowel. 
‘Total Colectomy’ was defined as total colectomy (including sub-total colectomy) and 
panproctocolectomy. Any other procedure was defined as ‘Other’. 
 
Dukes’ staging was defined by stage at diagnosis as recorded in the NCDR or if staging data 
was recorded as something other than Dukes’ (e.g. TNM), it was calculated from that. Time 
from admission to stent was defined by subtracting the date of admission from the date of the 
stent. 
 
Data were analysed using Stata™ Version 12.1 (StataCorp, 4905 Lakeway Drive,College 
Station, Texas 77845 USA). Chi Squared was used to compare outcomes across categorical 
variables. The Chi Square statistic is a commonly used test to assess for relationships 
between categorical variables. It assumes that there is no relationship between variables and 
that the outcome of interest is independent. It is however sensitive to sample size (i.e. large 
sample size will almost certainly give you a statistically significant p value). Statistically 
significant p values must therefore be viewed in the context of the sample size, and 
allowances in their interpretation made accordingly (e.g. with a huge sample size, a p value of 
p=0.05 is not particularly significant). Nevertheless, the Chi Square statistic is a commonly 
used test in most ‘big data’ publications and was again used here to for ease of cross 
comparison of results.   
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11.3. Results 
Between 1998 and 2010, 1378 patients underwent insertion of an endoluminal stent, with a 
year on year rise in stent use within the English NHS (Figure 30). In 477 patients the stent was 
the only recorded (surgical) treatment for that patient’s disease, whilst 901 were inserted as a 
bridge to surgery, of which 785 (86.5%) were inserted electively and 119 (13.2%) as an 
emergency. 
11.3.1. Figure 30: Stent Use in the English NHS 1998-2010 
 
 
The vast majority of stents inserted as a bridge to surgery were for left sided/ rectal 
malignancies (798, 88.6%), with the remaining 103 stents inserted for right sided or ‘Colon Not 
Otherwise Specified’ malignancy (103, 11.4%). Approximately two thirds were inserted for 
Dukes’ stage C or D disease (37.3% (Dukes’ C) and 22.2% (Dukes’ D) respectively) and one 
third for Dukes’ stage B disease (29.9%). Sex distribution was again approximately one third/ 
two thirds; 37.4% bridge to surgery patients were female and 62.6% male (Table 16). Median 
time from stent insertion to major resection in bridge to surgery patients was 24 days (IQR 12-
46 days). 
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11.3.2. Table 16: Characteristics of Patients who received an 
Endoluminal Stent prior to Major Resection or underwent Major 
Resection alone 
Characteristics of Patients Undergoing Endoluminal Stent Insertion and Stoma or Bypass 
Formation Prior to Major Resection or Major Resection Alone 
  
Stent as Bridge to 
Surgery 
Surgery Only 
 n % n  % 
Sex     
Male 564 37.4 131,779 55.2 
Female 337 37.4 106,882 44.8 
Dukes’ Stage     
A 12 1.3 27973 11.7 
B 269 29.9 80572 33.8 
C  336 37.3 79955 33.5 
D  200 22.2 21083 8.8 
Unknown 84 9.3 29078 12.2 
Age     
<60 181 20.1 41434 17.4 
60-69 232 25.7 63920 26.8 
70-79 302 33.5 84009 35.2 
>80 186 20.6 49298 20.7 
Charlson     
0 591 65.6 174120 73.0 
1 162 18.0 31089 13.0 
2 94 10.4 24338 10.2 
>/=3 54 6.0 9114 3.8 
IMD      
Least Deprived 189 21.0 48474 20.3 
2 178 19.8 52901 22.2 
3 179 19.9 51141 21.4 
4 196 21.8 46735 19.6 
Most Deprived 159 17.6 39410 16.5 
 
Patients receiving a stent as a bridge to surgery displayed little difference when compared by 
age to those who went straight to surgery but had more co-morbidities (Charlson Score ≥3, 
6% vs. 3.8%), were more socioeconomically deprived ((Deprivation Quintile 5 17.6% vs. 
16.5%) and had more advanced disease (Dukes’ C 37.3% vs. 33.5%, Dukes’ D 22.2% vs. 
8.8%).  
30-day mortality was higher amongst those who had a stent as a bridge to surgery compared 
with those who underwent surgery alone (Table 17).  
116 
 
 
 
11.3.3. Table 17: 30-day Post-Operative (Major Resection) 
Mortality by Stent as Bridge to Surgery against Surgery Alone 
All Operations 
Bridge category 
Status at 30-days post major resection 
Alive Dead 
n % n % 
Stent as Bridge to Surgery 826 91.7 75 8.3 
Surgery Only 223,478 93.6 15,183 6.4 
Total 224,304   15,258   
*N.B. Those who underwent stoma alone or bypass surgery have been excluded from this table. 
 
Rate of stoma formation following both emergency and elective operation in those who had a 
stent as a bridge to surgery was higher in those with colon cancer and broadly similar in those 
with rectal cancer (Table 18). 
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11.3.4. Table 18: Rates of stoma formation for patients with colon 
and rectal cancer following endoluminal stent insertion (when 
used as a bridge to surgery) 
Stoma at Major Operation 
Colon- Emergency Operation 
 Stoma No Stoma 
 n % n % 
Stent as Bridge to Surgery 73 70.2 31 29.8 
Surgery Only 11198 34.1 21604 65.9 
Colon- Elective Operation 
 Stoma No Stoma 
 n % n % 
Stent as Bridge to Surgery 71 66.4 36 33.6 
Surgery Only 21554 14.9 122874 85.1 
     
Rectum- Emergency Operation 
 Stoma No Stoma 
 n % n % 
Stent as Bridge to Surgery 12 80.0 3 20.0 
Surgery Only 1491 79.1 393 20.9 
Rectum- Elective Operation 
 Stoma No Stoma 
 n % n % 
Stent as Bridge to Surgery 71 66.4 36 33.6 
Surgery Only 43379 72.8 16168 27.2 
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In comparison, endoluminal stent use as a bridge to surgery appeared to result in a lower rate 
of stoma formation (at major resection) than when a stoma or bypass procedure had been 
undertaken preceding major resection (Table 19). 
11.3.5. Table 19: Rate of stoma formation (at major resection) for 
patients undergoing a bypass procedure or stoma prior to major 
resection 
Stoma at Major Operation 
Colon- Emergency Operation 
 Stoma No Stoma 
 n % n % 
Stoma or Bypass as Bridge to Surgery 20 43.5 26 56.5 
     
Colon- Elective Operation 
 Stoma No Stoma 
 n % n % 
Stoma or Bypass as Bridge to Surgery 555 61.6 346 38.4 
     
Rectum- Emergency Operation 
 Stoma No Stoma 
 n % n % 
Stoma or Bypass as Bridge to Surgery 22 53.7 19 46.3 
     
Rectum- Elective Operation 
 Stoma No Stoma 
 n % n % 
Stoma or Bypass as Bridge to Surgery 1,034 36.3 1,812 63.7 
 
Sixty five (65) stents which were inserted as a bridge to surgery failed over the course of the 
study period (7.2%), necessitating operative intervention within 48 hours of their insertion (and 
were therefore included as ‘Emergency’ resections in previous analyses). 33 patients (3.7%) 
required multiple stent insertions prior to their major resection (but were classified a ‘bridge to 
surgery’ for the purposes of analysis).  
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11.4. Discussion 
The evolution of endoluminal stents in the management of obstructing colorectal cancer 
represents not only technical innovation but also the clinician’s desire to find new and better 
ways of managing these complex patients. With this in mind, it is hardly surprising therefore 
(as shown by our results), that stents have been taken up enthusiastically by clinicians and 
are regarded by patients as a more attractive alternative to major operative intervention, 
particularly in the emergency or palliative settings187.  
 
The majority of the stents placed in this study were for use as a ‘bridge to surgery’ and whilst 
this remains a key part of the rationale behind stent use, especially in the context of stubbornly 
high emergency admission rates (and the potential to ‘convert’ a patient into a planned 
operation), modern practice now includes use of many more stents for palliation. It is likely that 
use of endoluminal stents in modern (i.e. 2018) colorectal cancer practice is very different to 
that of the period reported here188. Nevertheless, when used as a ‘bridge to surgery’, there is 
now a wealth of evidence in the medical literature (e.g. the ESCO trial) that stent use is 
associated with a reduction in stoma formation rate, a body of evidence that contradicts the 
findings of this study185,188,189.  
 
Stoma formation rates for patients undergoing major resection following stent placement as a 
bridge to surgery may have been higher in this study for a variety of reasons. This study 
covers the mainstream introduction of stents from a research tool to comparative ‘everyday’ 
use. Clinicians will have been ‘discovering’ the role of endoluminal stents in colorectal 
practice. Patients selected to receive a stent may well have been more likely to have had 
advanced disease, to have been admitted as an emergency and have more co-morbidities 
than those selected for immediate surgery (as shown in our results), which by default would 
make the operating surgeon more wary of performing a primary anastomosis. There remains 
the question of stent perforation and converting a patient who may have potentially curative 
disease to one with incurable, metastatic disease. Whilst there is today a greater body of 
evidence regarding this risk, the results of this study very much cover a period where the 
answer remained unknown. What is clear from our results is that stent use was associated 
with a much lower risk of stoma formation at major resection when compared to formation of a 
defunctioning stoma or bypass procedure. In this context, stent use offers clear advantages; 
there is no need for the patient to undergo a second general anaesthetic for their major 
resection and no need for a second major procedure (i.e. major resection following stoma 
formation/ bypass). That the 30-day mortality rate following major resection was higher in 
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bridge to surgery patients most likely represents the ‘higher risk’ nature of bridge to surgery 
patients, rather than any direct effect of the stents themselves. 
 
The risk of tumour perforation (up to 11.5%) and conversion from curable to metastatic 
disease with endoluminal stent use remains very real and is a question that has not yet been 
fully answered190. Previous studies have been stopped due to high rates of tumour perforation 
and whilst the ESCO trial showed that bridge to surgery patients had lower stoma formation 
rates than those who underwent emergency surgery (with equivalent oncological outcomes), 
this was limited by comparatively small patient numbers and a maximum 3-year follow up 
period183,184,189. The CREST trial found the same, but was again limited by only 1 year of follow 
up166. A recent review of 5-year disease recurrence in patients with and without perforation 
following stent placement found an adjusted hazard ration of 1.4 (for recurrence) against for 
those who had had a perforation191.  
 
Endoluminal stents undoubtedly have a developing role to play in the management of the 
emergency colorectal cancer patient.  Suárez and Jimenez-Pérez in a recent review of long-
term outcomes following stent use as a bridge to surgery in obstructed colorectal cancer 
patients noted that stented patients had a higher lymph node yield at major resection, received 
earlier adjuvant chemotherapy and were more likely to have undergone a laparoscopic 
resection192. Other authors have noted a significant increase in those achieving primary 
anastomosis at their major resection193,194.  
 
Thus in summary, it is clear that endoluminal stents offer certain advantages for carefully 
selected patients. They are not (like most novel technologies) the panacea they were first 
thought to be. It is likely that the higher rate of potential recurrent disease/ perforation may 
make clinicians approach stents with caution in younger patients. On the other hand, the 
opportunity to optimise a patient for surgery, a greater chance of primary anastomosis and 
greater likelihood of a laparoscopic procedure may make stents more appealing in the elderly 
population (where risk of late recurrence is perhaps less of a concern). As stent technology 
improves and as clinician experience increases, it is likely that endoluminal stents will have an 
increasing role to play in the management of the emergency colorectal cancer patient. In 
relation to English colorectal cancer care, refinement of ‘when and how’ endoluminal stents 
are used may offer particular advantages, especially when dealing with the known subset of 
patients who present late with aggressive disease, from which England appears to suffer. 
121 
 
 
Being able to offer these patients a planned operation, with potentially better oncological 
outcomes (i.e. higher lymph node yield, earlier adjuvant chemotherapy) may be another 
‘marginal gain’ we may be able to achieve in improving poor English colorectal cancer 
outcomes.  
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12. Overall Discussion 
That outcomes for the treatment of colorectal cancer in England and Wales have improved 
over the last 40 years is clear. One-year net survival from colorectal cancer in England and 
Wales in 1971-2 was 46.2%; by 2010-11, it had improved to 75.7%41. Five-year survival has 
also undergone a similarly impressive increase - from 25% in 1971-2 to 59% in 2010-1141. Yet 
outcomes still appear to trail behind those reported in Europe, Oceania and the United States. 
It would certainly seem that England and Wales started from a low baseline; the age 
standardised incidence rate for men with colorectal cancer in 1985 was 38.8 (per 100,000) in 
Western Europe whilst in the United States it was 48.2. In comparison, mortality at the same 
time in Western Europe was 21.4 and in the United States 17.4195,196. 
 
Colorectal cancer in England is still mainly a disease of the elderly with 43% cases being 
diagnosed in those aged ≥75 years197. Whilst there is a recognised rising incidence of CRC 
amongst younger patients, the vast majority of patients are still aged over 60198. As 
demonstrated in this study and discussed previously, it is important not to ignore this rising 
incidence in younger patients, especially as they potentially have the greatest longevity to gain 
from early diagnosis and treatment. Nevertheless, it is likely the elderly will continue to 
constitute the bulk of patients with CRC and the United Kingdom, like most developed nations, 
has a rapidly rising elderly population (in 1976, 14.2% of the population were aged over 65, by 
2016 this had reached 18% and is projected to reach 24.7% by 2046)199. How increasing age 
and co-morbidity affects survival in CRC was usefully demonstrated in a study by Gross et. al. 
Using population based cancer registry data linked to administrative claims data, they were 
able to demonstrate a reduction in life expectancy from 19.1years (in a man aged 65 
diagnosed with Stage 1 CRC with no chronic conditions), to 12.4 years for those with 1 or 2 
chronic conditions, to 7.6 years in those with ≥3 conditions). A similar decrease in survival was 
seen in women and an even greater impact (with increasing numbers of chronic conditions) in 
those aged ≥81 years200.  
 
The results of our study showed a clear fall, at a population level, in the number of elderly 
patients admitted as an emergency over the study period and this may indeed represent some 
of the national level changes in cancer care beginning to take effect (e.g. two-week wait). 
Nonetheless, those aged >80 still made up the greatest proportion of emergency admissions 
and still had the highest mortality from operative intervention at 30 and 90-days, a finding 
replicated in other, similar studies63,201.  
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It would also appear that England has a higher proportion of patients who present with 
aggressive disease which is rapidly fatal (in comparison to other European countries)142. If this 
pattern were repeated when compared to American and Oceanic patients, this may go some 
way to explaining some of the differences in outcomes seen between England and these 
countries, despite the efforts that have been made within the NHS to diagnose CRC earlier 
(through health promotion, patient education and screening).  
 
It is highly likely that the beneficial effects of screening were not fully illustrated within this 
study. Bowel cancer screening was only introduced in 2006 (at a population level) and the 
‘lead time’ for its positive impact on rates of emergency admission and stage of diagnosis was 
far too short to be recorded here. In an exceptionally cruel twist of fate the ex-Health Secretary 
who helped introduce the NHSBCSP has recently been diagnosed with (Stage III) colorectal 
cancer202. Lord Lansley notes that he only saw his GP following ‘nagging’ by his wife, but that 
had screening with flexible sigmoidoscopy been introduced as he intended, it is likely his 
tumour may have been detected earlier203. Population level data, as used here, has a role 
‘front and centre’ in providing the evidence, both from a health and economic perspective, of 
the efficacy of bowel cancer screening and the information that population level studies can 
provide should be exploited to the full. 
 
Nevertheless, to attribute the on-going differences in outcome between England and other 
high-income countries to patient demographics and disease biology alone would be too 
simplistic. The United Kingdom has an alternative set-up of its primary care services 
compared to its European neighbours in the role of the General Practitioner (GP) as 
gatekeeper to secondary care services. In other high-income countries, it is much more 
common for patients to self-refer to secondary care with their particular ailment (e.g., a patient 
with rectal bleeding may well make an appointment directly with a gastroenterologist/ 
colorectal surgeon). As the secondary care physician is primarily interested in the condition for 
which the patient has attended, they are likely to offer investigation of these symptoms more 
quickly and perhaps more aggressively than the general practitioner who must consider the 
patient’s holistic needs and other co-morbid conditions204. It is not helped by the fact that the 
primary symptoms of CRC (abdominal pain, fatigue, abdominal mass, rectal bleeding etc.)  
can be vague and attributed to other conditions; as such it has been estimated that up to a 
third of patients with CRC experience diagnostic delay86. This effect is likely to be amplified in 
the elderly and in those with multiple co-morbidities. The difficulty in diagnosis, (combined with 
124 
 
 
the potential for diagnostic delay), the conceivable reluctance of the elderly population to 
‘bother the doctor/ ‘stiff upper lip’ and recognised increasing incidence with ageing may go 
some way to explaining the resilience of poor English colorectal cancer outcomes, especially 
in light of high numbers of patients presenting late, as an emergency and with aggressive 
disease. Again, population level data may have a role in providing evidence for the most 
efficient use of limited NHS resources. For example, population level data may be able to 
provide new insights into the most efficient use of services such as the ‘Two Week Wait’ 
and/or be able to provide evidence for new, more effective referral pathways for primary care, 
based on symptom analysis and likelihood of detecting disease. 
 
Our study supports other reported data that emergency admission rates, mortality and length 
of stay fell between 1998- 2010205. Emergency admission rates have likely improved through 
the aforementioned patient education and awareness but also through the introduction of 
screening and initiatives such as the 2-week wait. The two-week wait initiative was first 
introduced in 2000 through the NHS Cancer Plan but has remained controversial since its 
inception. There appears to have been widespread implementation of the mechanisms 
necessary to meet the requirements of the two-week wait within the English NHS, but poor 
overall compliance, with a limited impact on rates of emergency admission168. It has been 
noted by several authors that the cancer detection rate with two-week wait referral patients are 
poor (and decreasing) but that the increasing volume of referrals under the two week rule are 
impacting on routine referrals, a group who contribute to a significant number of colorectal 
cancer diagnoses93,117,120,168. Indeed, Leung et al, in an analysis of 1100 two-week wait 
referrals over a 12 month period noted that more cancers were diagnosed by urgent referral, 
emergency admission, routine referral or screening than through the two-week wait system. 
They also noted that symptomatic patients tended to have Dukes’ B or above disease, whilst 
those identified through screening were usually Dukes’ A; a finding repeated by Chohan et al. 
who found that whilst two-week wait patients were  seen quicker, on diagnosis they tended to 
have more advanced disease165,167. The data provided within this study should support the 
argument for the case that whilst well intentioned, the two-week wait system is not bringing 
about the changes in (colorectal at least) cancer diagnosis that was anticipated nor expected. 
New methods of assessing patients with potential colorectal cancer symptoms must be 
identified. Population level data provides huge scope for the linking of primary and secondary 
care data to help produce algorithms to characterise those most at risk and to streamline 
referral services to secondary care.  
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Thus ,it would appear that the two-week wait system has had a limited impact on both 
emergency admission rates and outcomes, but that, as stated above, population level data 
may have a role in improving this. It would seem that screen detection of early cancer through 
faecal occult blood testing/ faecal immunochemical testing/ sigmoidoscopy offers a more 
efficient mechanism for both reduction of emergency admission with concurrent improvement 
in outcomes. Certainly, the early data provided here, supports the case for screening of 
colorectal cancer, with good evidence that screening results in earlier diagnosis and therefore 
presumed better outcomes. Nonetheless, for those who do come to surgery, there can be little 
doubt that the introduction of minimally invasive/ laparoscopic surgery, combined with 
enhanced recovery protocols has helped drive the decreasing length of stay reported here and 
that it is likely modern day figures would report further improvements192.  
 
The introduction of laparoscopic surgery as recorded here is an excellent example of how 
population level data can be used to track improvements in patient outcomes through the 
introduction of new technology. New technology (e.g. laparoscopic surgery, endoluminal 
stents) inevitably involves a learning curve before its abilities and limitations are fully 
understood. At a local level, this may prevent uptake of, or persistence with new technologies 
at the expense of patient outcomes. Population level data allows us to chart the impact of 
these technologies and to gauge their effectiveness, without the influence of local bias. It 
further allows us to evaluate where these resources may be best placed or how they may be 
best delivered for maximum impact on patient care.  
 
Mortality rates at both 30 and 90 days (for English colorectal cancer patients) reported here 
were consistent with rates reported elsewhere in the medical literature63. They also followed 
the decreasing trend in 30-day mortality reported both for England and Europe63,139,206,207. 
There has been considerable debate over recent years in the medical literature as to the 
appropriateness of using 30-day mortality alone and whether this was in fact ‘hiding’ mortality 
that is revealed at 90-days192,194. The results presented here confirm an improving trend in 
relation to mortality at both 30 and 90-days over the period of the study but also highlight the 
marked increase in mortality seen in patients aged >80 at all time periods. The analysis of 
mortality rates by Trust also replicates the wide variations in outcomes reported by others for 
English colorectal cancer patients, although there appeared to be little association with volume 
of work and interestingly, those Trusts with a high elective mortality were not necessarily the 
same as those with a high emergency mortality62,63.  
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This variation in mortality rates will of course, have a variety of causes, not least because of 
variability in the demographics that individual hospital Trusts serve. Nonetheless, there is 
increasing evidence that a key factor behind the variability in outcome in England relates to 
the provision of critical care beds for high risk surgical patients and of a ‘failure to rescue’ the 
deteriorating patient102,104,208,209. Critical care bed provision in England (and the United 
Kingdom as a whole) has been recognised as an issue for over 20 years208. The United 
Kingdom has, on average far fewer critical care beds than other, equivalent income European 
countries and yet the number of ICU beds in a hospital has been shown to be an independent 
predictor of decreased mortality amongst high risk general surgical patients209.  
 
The availability of and access to ICU beds for the post-operative colorectal cancer patient 
represents only one facet of their care however. Alongside ICU bed provision must be the 
ability to recognise and react to the deteriorating patient. Again, the United Kingdom compares 
poorly to other equivalent countries in relation to the number of intensivists caring for patients. 
UK Government statistics report that the maximum number of patients one consultant 
intensivist may look after at any one time is 15. In the Netherlands this ratio is 1:12 and in 
Sweden 1:6. Further, pharmacy services in the United Kingdom are only required to be 
provided in working hours Monday to Friday, whereas many other countries require these 
services to be available 24/7210.Thus opportunities to address a patient’s deteriorating 
condition may be being missed, with associated deleterious effects on outcomes. 
 
ICU bed provision, number of intensivists and such like are linked to ‘Failure to Rescue’ the 
deteriorating patient. Failure to rescue simply represents a hospital’s ability to allow patients 
who suffer a serious complication to survive. Henneman et al. have reported that in relation to 
complication rates, high mortality hospitals only have a slightly higher rate than their low 
mortality counterparts do102. However, the failure to rescue rate was 3 times higher in high 
mortality hospitals. Henneman et al in a separate study also go on to report that whilst high 
volume and teaching status are associated with decreased failure to rescue rates, there is 
also a significant association with higher levels of ICU provision (and decreased mortality)211.  
 
Almoudaris et al report that in relation to English colorectal cancer units, there is significant 
variation in failure to rescue rates and in particular, through looking at management of surgical 
complications, significant variability in complication management. They report that reoperation 
rates are similar between hospital Trusts with the highest and lowest mortality rates but are 
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widely different when it comes to failure to rescue rates (and therefore by default, in their 
management of serious complications)104. Recent years have seen recognition of this problem 
and there are now on-going initiatives to audit management of emergency laparotomy/ serious 
complications (e.g. National Emergency Laparotomy Audit) in order to improve standards and 
drive outcomes.  
 
The variation in Failure to Rescue rates throughout England may well go some way to 
explaining the variability in mortality rates demonstrated here, despite accounting for volume 
of work. Providing evidence of variability in Failure to Rescue through population level data is 
likely to be vital for the justification of increased expenditure on critical care facilities within 
England/ the United Kingdom. It will only be through showing how lack of these facilities 
affects outcomes (particularly in colorectal cancer), that we will be able to drive forward such 
changes. 
 
In isolation however, ICU bed numbers and failure to rescue rates do not explain England’s 
on-going poor record in relation to CRC outcomes. Yet, when combined with an ageing 
population, who often present late (and in an acute fashion), a picture begins to emerge of 
why England has failed to ‘catch up’ with similar income level countries. Certainly, the results 
of this study confirm that risk factors for emergency admission remain the same (old age, 
female sex, increased co-morbidity and socio-economic deprivation) as do risk factors for 
mortality post-surgery. There is also variation in hospital performance and again, this is 
displayed in our results58,63,104,209. Therefore, to improve outcomes, particular attention should 
be paid to the on-going efforts aimed at earlier diagnosis, the lack of critical care beds and the 
management of patients with serious complications. Failure to rescue would seem to be one 
of the key challenges facing clinicians who must manage an increasingly elderly and frail 
population with CRC.  Improving English colorectal cancer outcomes will require a multi-
faceted approach that targets problems within primary and secondary care and even at a 
societal level (e.g. how much we as a society choose to spend on health).  
 
How the English surgical community responds to variation in outcomes will also be of great 
importance in the drive to improve standards of care and outcome (in particular in relation to 
‘outlying’ hospital trusts). Whilst attempts should be made to reduce variation in practice, this 
should not be done on the basis that poor outcomes are always related to poor individual 
clinical care, with no effort made to look at systemic failings or the context in which that care is 
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provided. Initiatives such as the reporting of individual surgeon outcomes may be well 
intentioned, but provide no information as to the influence of the nature of the population that 
surgeon serves, the effect of chance or the influence of the practices of the multitude of other 
health care professionals involved in a patients care, all of whom are necessary for safe 
surgical practice. It is easy to blame the captain for the sinking of the Titanic, in his haste to 
reach New York. Yet there is evidence that the poor quality of the rivets used in the  
construction of the Titanic may have caused the hull to fail, following a comparatively low 
energy impact with the iceberg (the poor quality rivets were used by Harland and Wolff 
because of pressure to finish the Titanic quickly)212.  
 
Surgeons and hospital trusts should be supported to improve their outcomes through the 
dissemination of good practice that has been shown to be effective in their particular locality or 
region. Population level data and studies such as this have a key role to play in providing ‘big 
picture’ evidence of how outcomes are changing (and in relation to others) and illuminating 
issues smaller studies may miss. If overall screening take-up is 60% of those invited, if take-
up is 90% in one area and only 30% in another, it is clear where efforts to improve take–up 
should be focused. Population level data may also be used to help change practice through 
the linking of data from comparable hospital trusts/ health systems, providing much clearer 
evidence of which interventions are likely to have the greatest impacts and where. 
Nevertheless, vigilance should be used to ensure that population level data is not abused to 
suit individual or political aims.  
 
Whilst the findings of this study are similar of others in relation to English CRC outcomes (i.e. 
improving outcomes but still behind those of Europe, North America etc.), these results also 
continue to question whether English CRC results are being unfairly criticised. The previous 
criticisms of Autier and Boniol in relation to the poor quality of UK cancer registration relate to 
data from the early 1990’s and have now been resolved72. England and the United Kingdom 
now enjoy some of the most complete and accurate cancer data registry in the world.  Indeed 
it is perhaps unfair to compare English with European outcomes and even with those in parts 
of the United States, when it is well recognised that some countries (notably France, 
Germany, Spain and Italy) have poor and incomplete records; we are therefore not comparing 
‘apples with apples’213. Further, by the nature of population level data and cancer registration, 
analysis must always be historical rather than contemporaneous. Huge effort went into (and 
continues to go into) improving cancer outcomes in England and the United Kingdom over the 
period covered by this study (Calman-Hine report, NHS Cancer Plan, Cancer Reform 
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Strategy). It is likely that only now are we truly beginning to see the effects of these 
endeavours ‘feeding through’ in the improved outcomes seen in reports such as EUROCARE-
5214.  
 
The EUROCARE-5 report is not without its problems however. Of the 29 countries who 
participated, 21 had 100% cancer registration, but 8 did not215. There remain issues regarding 
the lack of sociodemographic information, investigations patients underwent to confirm their 
diagnosis and staging, the treatments administered, disease recurrence and the second line 
treatments used215. Stating that England has poor outcomes when a comparison is made to 
countries with incomplete data is demonstrably unfair. It is a rare occurrence indeed, when 
positive outcome data is not included in any data submission. 
 
Furthermore, EUROCARE-5 covers a period of upheaval in the European population. Over 
recent years, there has been significant migration both within and into Europe. If a patient is 
diagnosed in their country of work but returns to their country of origin to die, this artificially 
inflates the survival rate of the country of work and decreases that of the country of origin. 
Again it will only be through use of population level data that we are able to keep track of 
these changes (and account for them)215. Finally, England remains a country of huge income 
inequality. Households in the top 10% of income have a disposable income that is almost 9 
times that of the bottom 10%216. If a population is unhealthy and therefore not fit for curative 
treatment, then no amount of enhanced cancer services will improve outcomes. 
 
Improving cancer outcomes is not only about the proportion of individuals who can undergo 
and survive major resection of course. No matter what systems are in place, there will always 
be a certain number of patients who present late with incurable disease, or suffer disease 
recurrence. How these individuals are managed is equally important to those who undergo a 
major resection. In this study, the use of endoluminal stents as a bridge to surgery was 
evaluated. It is clear that there has been an enormous increase in their use since their 
introduction by Dohomoto in 1991. The results presented here would also appear to concur 
with the results of the CREST and ESCO trials in that their use as a bridge to surgery (in the 
relief of an obstructing tumour) appears to offer a higher likelihood of primary anastomosis at 
time of major resection185,189. What neither CREST nor ESCO, nor our study here (although 
this, or similar datasets would be most appropriate to answer this question) have adequately 
evaluated is the effect on longer-term survival of endoluminal stent use. In the immediate 
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term, stents offer obvious advantages to the patient in relief of the obstruction and the 
opportunity for optimisation prior to surgery. The effect on long-term survival of those 
unfortunate enough to suffer a stent related perforation remains to be seen. Some authors 
have reported no effect on long-term survival with stent related perforations (Verstockt et al., 
Ribeiro et al.) whilst others have reported 5-year survival rates of 61% in those without a stent 
related perforation and 37% in those with (Avlund et al.)191,217,218.  
 
Endoluminal stents were introduced into clinical practice over the duration of this study and 
whilst this study has focused on the changing outcomes of those patients suitable for major 
resection, evaluation of the treatments offered to those not suitable for surgery must occur in 
order to complete the picture. Endoluminal stents represent just one part of a changing field of 
non-surgical treatments (e.g. chemotherapy, radiotherapy, chemoembolization, 
radiofrequency ablation), the outcomes of which must be collated, evaluated and their use 
tailored to patient need, once again a role to which population level data is highly suited. 
 
Our study, like all population-based studies suffers from its analysis of historical data and of a 
necessarily limited scope (those undergoing major resection). It is also limited by the issues 
affecting other databases raised here (accuracy and completeness of recording) and by lack 
of confounding information, e.g. sociodemographic effects have only been taken into limited 
account but their effect may be much greater than that demonstrated here. It does however 
evaluate a complete population over time and as such provides an excellent ‘snapshot’ of the 
changing face of English colorectal cancer outcomes. It avoids problems such as selection 
bias associated with smaller studies and demonstrates how interventions such as the NHS 
Cancer Plan and the introduction of screening for colorectal cancer are beginning to make a 
tangible difference to outcomes. There will be no magic bullet for English colorectal cancer 
outcomes, but population level databases have a great deal to contribute and an on-going role 
to play in the analysis of outcomes and evaluation of the progress being made.  
 
Analysis of population level datasets may allow comparisons of survival of matched patients 
offered different treatment modalities (including non-operative treatments) to be made. These 
outcomes could then be linked to quality of life scores and other qualitative measures of 
cancer treatment (beyond current Patient Reported Outcome Measures). In time therefore, a 
patient may be offered a suite of potential treatment options from which they are able to 
choose those that best suit their own needs; after all there is little point chasing quantity of life 
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if there is no quality of life.  The linking of outcome data to demographic data may reveal 
treatments best suited to different population groups and may support or refute variations in 
clinical practice depending on the population served. In short, population datasets present 
challenges, not least through their size and the ethical ownership and management of that 
data, but their potential to answer questions not previously thought possible is unrivalled. 
 
13. Conclusions 
Without doubt, colorectal cancer outcomes in England are improving. Numbers of patients 
admitted as an emergency are falling and for those suitable for major resection, mortality is 
decreasing. Systems are now in place to improve rates of early diagnosis through patient 
education and nationwide screening programs. There is also an increasing realisation of the 
role of perioperative care through use of pre-assessment and enhanced recovery protocols. 
 
Significant challenges remain however. As early diagnosis is the key to successful treatment 
in colorectal cancer, on-going efforts must be made to identify patients in the initial stages of 
their disease. Further, the systems must be in place to offer those patients prompt and 
individually tailored treatments; current systems such as the two-week wait and 31/62 day 
targets may not be the best method of driving standards and should continue to be 
challenged.  
 
Major resectional surgery for colorectal cancer represents a huge physiological insult to a 
patient, no matter what age they are. In a disease where the majority of patients are elderly, 
often with co-morbidities, patients must be optimised for surgery as much as possible 
beforehand, but there must also be adequate facilities to care for them thereafter. There 
seems little point investing in earlier diagnosis if we are then unable to perform a safe 
operation from which the patient has the best possible chance of surviving. The variability in 
failure to rescue must be addressed not only through increased provision of critical care beds 
and the dissemination of good practice but also through initiatives which have already begun 
such as the perioperative care physician and Care of the Elderly physicians reviewing post-
operative colorectal cancer patients.  
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Care for those who are unsuitable for surgical intervention must also be reviewed in the same 
light as those for whom surgery is an option. Their treatment must be optimised and novel 
technologies such as endoluminal stents have a role to play in avoidance of operative 
procedures (e.g. defunctioning stoma) and in providing the patient with the greatest quality of 
life for as long as possible. Our efforts to improve outcomes must not solely focus on surgery. 
 
Out with the surgical sphere of influence, there remains huge variability in income distribution 
and access to healthcare in England. There will always be variability in income, but there is no 
reason in a nationalised health service that there should be variability in access to healthcare. 
Further efforts need to be made to address these shortcomings, alongside efforts to improve 
healthy living standards. Outcomes cannot improve if the population itself is not well enough to 
undergo the treatment.  
 
At present, we have achieved only a ‘frame shift’ in English colorectal cancer outcomes. Our 
outcomes have improved and it is questionable whether previously reported poor outcomes 
are indeed a true reflection, but so have everyone else’s. In order for us to ‘catch up’ 
improvements must be made in three domains: access to healthcare and improved public 
health, early diagnosis through education and screening and access to optimal treatments and 
post-operative care, in particular focusing on the needs of an increasingly frail and elderly 
population. Population level data has a key role to play in documenting changing outcomes 
but also in identify where effort and resources may best be allocated. Much work has been 
done to improve English colorectal cancer care, but there remains much work to do.  
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